cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy and who has a tumor mutational burden (TMB) of 18.0, how likely is he to respond to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy and who has a tumor mutational burden (TMB) of 18.0, how likely is he to respond to atezolizumab therapy? Review the patient's tumor microenvironment transcriptomic data, focusing on the expression patterns of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, using evidence-based reasoning, assess whether these findings suggest that the patient is likely to respond to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor’s immune microenvironment from a bladder biopsy, and his tumor mutational burden is 1.0. Based on these findings, what is his likelihood of responding to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor’s immune microenvironment from a bladder biopsy, and his tumor mutational burden is 1.0. Based on these findings, what is his likelihood of responding to Atezolizumab therapy? Examine the patient's transcriptomic data from the tumor microenvironment, paying particular attention to the gene expression profiles of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, based on current scientific evidence, determine whether these expression patterns indicate that the patient is likely to respond to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"I am managing a white female patient with bladder urothelial carcinoma who recently underwent a bladder biopsy, and we have obtained a transcriptomic profile of her tumor immune microenvironment. Given her tumor mutation burden (TMB) of 44.0, is there evidence to suggest that she would respond favorably to Atezolizumab therapy?","I am managing a white female patient with bladder urothelial carcinoma who recently underwent a bladder biopsy, and we have obtained a transcriptomic profile of her tumor immune microenvironment. Given her tumor mutation burden (TMB) of 44.0, is there evidence to suggest that she would respond favorably to Atezolizumab therapy? Review the patient's transcriptomic data from the tumor microenvironment, specifically evaluating the gene expression profiles of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Using current scientific evidence, assess whether these expression patterns suggest that the patient is likely to benefit from the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"My white female patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy and a tumor mutation burden (TMB) of 2.0. Based on these findings, is she likely to respond to Atezolizumab therapy?","My white female patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy and a tumor mutation burden (TMB) of 2.0. Based on these findings, is she likely to respond to Atezolizumab therapy? Please evaluate the patient’s transcriptomic data from the tumor microenvironment—specifically focusing on the gene expression profiles of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Based on the latest scientific evidence, determine whether these molecular patterns indicate that the patient is likely to respond favorably to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, does the transcriptomic profile of the tumor microenvironment suggest a potential benefit from Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, does the transcriptomic profile of the tumor microenvironment suggest a potential benefit from Atezolizumab therapy? Please review the patient's tumor microenvironment transcriptomic data, paying particular attention to the gene expression profiles of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. In light of the most current scientific evidence, assess whether these molecular markers suggest that the patient is likely to respond favorably to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"I have a white female patient diagnosed with bladder urothelial carcinoma. The tumor biopsy provided a transcriptomic profile of the immune microenvironment, and her tumor mutational burden is 6.0. Given this data, how likely is she to respond favorably to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. The tumor biopsy provided a transcriptomic profile of the immune microenvironment, and her tumor mutational burden is 6.0. Given this data, how likely is she to respond favorably to Atezolizumab therapy? Please analyze the patient's tumor microenvironment transcriptomic data, with a focus on the gene expression levels of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Based on the latest scientific research, determine if these molecular markers indicate a high probability of a positive response to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"For a Caucasian male patient with bladder urothelial carcinoma, whose kidney biopsy provided transcriptomic profiling of the tumor immune microenvironment and a TMB of 11.0, is he likely to respond to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose kidney biopsy provided transcriptomic profiling of the tumor immune microenvironment and a TMB of 11.0, is he likely to respond to atezolizumab therapy? Review the patient's tumor microenvironment transcriptomic data, concentrating on gene expression patterns for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, based on current scientific evidence, assess whether these markers are indicative of a favorable response to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"I am evaluating a White male with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 18.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","I am evaluating a White male with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 18.0. Based on these findings, how likely is he to respond to atezolizumab therapy? Examine the tumor microenvironment transcriptomic profile from the patient, focusing specifically on the gene expression levels of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, using evidence from recent scientific studies, determine whether these markers suggest that the patient is likely to respond favorably to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"I have a Caucasian female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutational burden is not available (reported as ""nan""). Based on this data, can we predict her likely response to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutational burden is not available (reported as ""nan""). Based on this data, can we predict her likely response to Atezolizumab therapy? Review the transcriptomic profile of the tumor microenvironment in this patient, with a particular focus on the expression levels of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, draw upon current scientific literature to assess whether these markers indicate a likely positive response to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment via a nan biopsy. Given his reported tumor mutational burden (TMB) value of 'nan', can we predict whether this patient is likely to respond to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment via a nan biopsy. Given his reported tumor mutational burden (TMB) value of 'nan', can we predict whether this patient is likely to respond to Atezolizumab therapy? Examine the transcriptomic profile of the patient's tumor microenvironment, focusing specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, using current scientific research, determine if the expression levels of these markers suggest that the patient is likely to respond favorably to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 2.0 mutations per megabase. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 2.0 mutations per megabase. Based on these findings, what is the likelihood that this patient will respond to atezolizumab therapy? Review the transcriptomic analysis of the patient's tumor microenvironment with a focus on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, using the latest scientific evidence, assess whether the expression levels of these markers indicate that the patient is likely to have a favorable response to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0, based on transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy, is there evidence to support a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0, based on transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy, is there evidence to support a favorable response to Atezolizumab therapy? Examine the transcriptomic data from the patient's tumor microenvironment, focusing specifically on biomarkers related to T cell exhaustion, cytotoxic T cells, monocytes, and macrophages. Then, based on the latest research, determine whether the levels of these markers suggest a favorable response to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"A white female patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a lymph node biopsy, and her tumor mutational burden is reported as ""nan."" Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a lymph node biopsy, and her tumor mutational burden is reported as ""nan."" Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Review the transcriptomic profile of the patient’s tumor microenvironment, concentrating on biomarkers indicative of T cell exhaustion, cytotoxic T cell activity, monocyte presence, and macrophage function. Then, using current research, assess whether the expression levels of these markers predict a favorable response to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy shows a tumor mutational burden of 9. Can we expect this patient to respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy shows a tumor mutational burden of 9. Can we expect this patient to respond favorably to Atezolizumab therapy? Examine the tumor microenvironment’s gene expression profile with a focus on identifying markers associated with T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, using the most recent research, evaluate whether these marker levels can predict a positive response to the treatment being considered.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"My patient, a White female diagnosed with bladder urothelial carcinoma, has a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutation burden of 4.0. Based on these findings, can we expect a favorable response to atezolizumab therapy?","My patient, a White female diagnosed with bladder urothelial carcinoma, has a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutation burden of 4.0. Based on these findings, can we expect a favorable response to atezolizumab therapy? Review the gene expression profile of the tumor microenvironment with particular attention to markers linked to T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, based on the latest research findings, determine whether the levels of these markers can serve as reliable predictors of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"A Caucasian male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, revealing a tumor mutation burden of 32.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, revealing a tumor mutation burden of 32.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Examine the tumor microenvironment's gene expression data, focusing specifically on markers for T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, using current research findings, assess if these markers reliably predict a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 21.0, is there evidence that he might benefit from atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 21.0, is there evidence that he might benefit from atezolizumab therapy? Review the gene expression data from the tumor microenvironment, specifically concentrating on markers of T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, based on current research, determine whether these markers can reliably predict a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor mutational burden is 10.0 and for whom we have transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor mutational burden is 10.0 and for whom we have transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Examine the gene expression profiles from the tumor microenvironment by focusing on markers of T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, using current research, evaluate whether these biomarkers can reliably indicate a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"In a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 38.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that the patient will respond favorably to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 38.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that the patient will respond favorably to atezolizumab therapy? Analyze the gene expression profiles within the tumor microenvironment, specifically examining markers of T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, review current scientific literature to determine if these biomarkers consistently predict a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment is available and who has a tumor mutation burden (TMB) of 7.0, what is the anticipated response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment is available and who has a tumor mutation burden (TMB) of 7.0, what is the anticipated response to Atezolizumab therapy? Review the gene expression data from the tumor microenvironment, focusing on markers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Subsequently, critically examine current scientific literature to determine whether these biomarkers reliably predict a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"Given a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the likelihood that he will respond favorably to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the likelihood that he will respond favorably to Atezolizumab therapy? Examine the gene expression profiles within the tumor microenvironment, paying special attention to markers associated with T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, review the latest scientific literature to assess whether these biomarkers reliably predict a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"For our White male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 15.0 and transcriptomic profiling of the tumor immune microenvironment from his biopsy, is Atezolizumab a viable treatment option?","For our White male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 15.0 and transcriptomic profiling of the tumor immune microenvironment from his biopsy, is Atezolizumab a viable treatment option? Review the gene expression patterns in the tumor microenvironment, focusing on biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Next, consult current scientific studies to determine if these biomarkers are reliable predictors of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of his tumor immune microenvironment via kidney biopsy and whose tumor mutational burden (TMB) is unavailable, what is the likelihood that he will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of his tumor immune microenvironment via kidney biopsy and whose tumor mutational burden (TMB) is unavailable, what is the likelihood that he will respond to atezolizumab therapy? Examine gene expression within the tumor microenvironment by focusing on specific biomarkers that reflect T cell exhaustion, the activity of cytotoxic T cells, the extent of monocyte infiltration, and macrophage function. Then, review the latest scientific literature to determine if these biomarkers reliably predict a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"My white male patient has bladder urothelial carcinoma, and I have obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy. Given that the patient's tumor mutation burden is not available, is there evidence to suggest that he is likely to respond to Atezolizumab therapy?","My white male patient has bladder urothelial carcinoma, and I have obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy. Given that the patient's tumor mutation burden is not available, is there evidence to suggest that he is likely to respond to Atezolizumab therapy? Evaluate gene expression in the tumor microenvironment by targeting biomarkers associated with T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Next, review the recent literature to determine whether these markers consistently predict a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"Given the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy in a white male patient with bladder urothelial carcinoma, and considering a tumor mutation burden of 18.0, what is the likelihood of a favorable response to atezolizumab therapy?","Given the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy in a white male patient with bladder urothelial carcinoma, and considering a tumor mutation burden of 18.0, what is the likelihood of a favorable response to atezolizumab therapy? Assess gene expression within the tumor microenvironment by focusing on biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, review the latest research to determine if these biomarkers reliably predict a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"In our Black male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by transcriptomic analysis from a ureter biopsy and a tumor mutational burden of 7.0, how likely is he to respond to atezolizumab therapy?","In our Black male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by transcriptomic analysis from a ureter biopsy and a tumor mutational burden of 7.0, how likely is he to respond to atezolizumab therapy? Evaluate gene expression in the tumor microenvironment by specifically analyzing biomarkers associated with T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Next, review current scientific literature to determine whether these biomarkers consistently predict a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 19.0. The tumor immune microenvironment was profiled transcriptomically using a bladder biopsy sample. Based on these findings, is it likely that the patient will respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 19.0. The tumor immune microenvironment was profiled transcriptomically using a bladder biopsy sample. Based on these findings, is it likely that the patient will respond favorably to Atezolizumab therapy? Assess gene expression within the tumor microenvironment by measuring biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, review the recent scientific literature to determine if these biomarkers consistently correlate with favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a TMB of 5.0. Based on these findings, is there evidence to suggest that he will respond favorably to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a TMB of 5.0. Based on these findings, is there evidence to suggest that he will respond favorably to atezolizumab therapy? Evaluate gene expression in the tumor microenvironment by quantifying biomarkers that reflect T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, review the latest scientific literature to determine whether these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these results, what is the likelihood that the patient will respond favorably to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these results, what is the likelihood that the patient will respond favorably to atezolizumab therapy? Assess gene expression within the tumor microenvironment by measuring biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, review the latest scientific studies to determine if these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), tumor transcriptomic profiling of the immune microenvironment from a bladder biopsy reveals a tumor mutation burden (TMB) of 8.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), tumor transcriptomic profiling of the immune microenvironment from a bladder biopsy reveals a tumor mutation burden (TMB) of 8.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the expression of genes within the tumor microenvironment by measuring biomarkers that reflect T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. After collecting these measurements, review recent scientific literature to determine whether these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"This white female patient with bladder urothelial carcinoma has a TMB of 13.0 based on transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy. Given these findings, how likely is it that she will respond to Atezolizumab therapy?","This white female patient with bladder urothelial carcinoma has a TMB of 13.0 based on transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy. Given these findings, how likely is it that she will respond to Atezolizumab therapy? Assess gene expression in the tumor microenvironment by quantifying biomarkers indicative of T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. After gathering these data, review current scientific literature to determine if these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled via transcriptomic analysis from a kidney biopsy and who has a tumor mutational burden of 16.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled via transcriptomic analysis from a kidney biopsy and who has a tumor mutational burden of 16.0, what is the likelihood of a favorable response to atezolizumab therapy? Evaluate gene expression in the tumor microenvironment by measuring biomarkers linked to T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Once these data are collected, review the latest research to determine if these markers are consistently associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy reveals a tumor mutational burden of 2.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy reveals a tumor mutational burden of 2.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy? Assess gene expression within the tumor microenvironment by quantifying biomarkers related to T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. After obtaining these measurements, review current literature to determine if these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma, for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden (TMB) data is unavailable. Considering these factors, what is the likelihood that the patient will respond to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma, for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden (TMB) data is unavailable. Considering these factors, what is the likelihood that the patient will respond to atezolizumab therapy? Quantify gene expression in the tumor microenvironment by measuring biomarkers associated with T cell exhaustion, cytotoxic T cell function, monocyte infiltration, and macrophage activity. Once you obtain these measurements, review the current literature to confirm whether these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"My white male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is he likely to respond to atezolizumab therapy?","My white male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is he likely to respond to atezolizumab therapy? Assess gene expression within the tumor microenvironment by measuring biomarkers that indicate T cell exhaustion, cytotoxic T cell function, monocyte infiltration, and macrophage activity. After collecting these data, review recent literature to determine if these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"A white male patient with bladder urothelial carcinoma presents with a tumor mutational burden of 20, and we have his tumor immune microenvironment transcriptomic profile from a bladder biopsy. Based on these findings, what is the likelihood that he will respond favorably to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma presents with a tumor mutational burden of 20, and we have his tumor immune microenvironment transcriptomic profile from a bladder biopsy. Based on these findings, what is the likelihood that he will respond favorably to atezolizumab therapy? Evaluate gene expression within the tumor microenvironment by quantifying biomarkers that reflect T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Once you have these measurements, review the latest research to determine whether these biomarkers are consistently linked with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a tumor mutational burden of 5.0, what is the likelihood that she will respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a tumor mutational burden of 5.0, what is the likelihood that she will respond to Atezolizumab therapy? Assess gene expression in the tumor microenvironment by quantifying biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Once you obtain these measurements, review up-to-date research to evaluate whether these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"My white male patient with biopsy-confirmed bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 38 and transcriptomic data characterizing the tumor immune microenvironment. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","My white male patient with biopsy-confirmed bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 38 and transcriptomic data characterizing the tumor immune microenvironment. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Measure gene expression in the tumor microenvironment by quantifying specific biomarkers related to T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. After obtaining these measurements, consult the latest research to determine if these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"The patient is a Caucasian male with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 6.0, with transcriptomic profiling of the tumor immune microenvironment obtained through kidney biopsy. Based on these findings, is he likely to respond to Atezolizumab therapy?","The patient is a Caucasian male with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 6.0, with transcriptomic profiling of the tumor immune microenvironment obtained through kidney biopsy. Based on these findings, is he likely to respond to Atezolizumab therapy? Quantify gene expression within the tumor microenvironment by assessing biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Once these measurements are obtained, review the most recent scientific literature to determine whether these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"My white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Assess gene expression in the tumor microenvironment by measuring biomarkers indicative of T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. After obtaining these data, review up-to-date research to determine whether these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"In a white male patient with bladder urothelial carcinoma (BLCA), whose tumor mutational burden is 13.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), whose tumor mutational burden is 13.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Evaluate gene expression within the tumor microenvironment by measuring key biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Once you have obtained these measurements, review the latest research to confirm whether these biomarkers are consistently linked with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and available transcriptomic data from a kidney biopsy of the tumor immune microenvironment, what is the likelihood of a response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and available transcriptomic data from a kidney biopsy of the tumor immune microenvironment, what is the likelihood of a response to Atezolizumab therapy? Assess gene expression in the tumor microenvironment by measuring biomarkers indicative of T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. After collecting these measurements, review the current literature to determine whether these biomarkers are consistently associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0 mutations per megabase, is it likely that she will respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0 mutations per megabase, is it likely that she will respond to Atezolizumab therapy? Evaluate gene expression in the tumor microenvironment by measuring biomarkers that reflect T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Once these data are collected, consult current literature to determine if these biomarkers are reliably linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"I have a Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0. We obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy. Based on these findings, do you anticipate she will respond to atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0. We obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy. Based on these findings, do you anticipate she will respond to atezolizumab therapy? Assess gene expression within the tumor microenvironment by quantifying biomarkers that indicate T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. After obtaining these measurements, review current scientific literature to confirm whether these biomarkers consistently predict better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"In a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a previous biopsy is available, but the TMB value is not defined (recorded as “nan”). Based on this information, what is the likelihood that the patient will respond to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a previous biopsy is available, but the TMB value is not defined (recorded as “nan”). Based on this information, what is the likelihood that the patient will respond to atezolizumab therapy? Measure gene expression in the tumor microenvironment by quantifying biomarkers for T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function. Then, review the current scientific literature to determine if these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"In a white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 12.0 and available transcriptomic profiling of the immune microenvironment from a lymph node biopsy, is there evidence to suggest that she would likely respond to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 12.0 and available transcriptomic profiling of the immune microenvironment from a lymph node biopsy, is there evidence to suggest that she would likely respond to atezolizumab therapy? Assess gene expression within the tumor microenvironment by quantifying biomarkers indicative of T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage functionality. After completing these measurements, review the current scientific literature to evaluate whether these biomarkers consistently correlate with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile has been characterized via bladder biopsy and who has a tumor mutational burden of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile has been characterized via bladder biopsy and who has a tumor mutational burden of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the expression of genes associated with T cell exhaustion, cytotoxic T cell activity, monocyte infiltration, and macrophage function within the tumor microenvironment. Then, review the current scientific literature to determine if these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 6.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 6.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Assess the expression levels of genes involved in T cell exhaustion, cytotoxic T cell responses, monocyte recruitment, and macrophage activity within the tumor microenvironment. Then, review recent scientific studies to determine whether these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"My patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 8.0. Based on these findings, is there evidence to support using Atezolizumab in this case?","My patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 8.0. Based on these findings, is there evidence to support using Atezolizumab in this case? Evaluate the gene expression profiles related to T cell exhaustion, cytotoxic T cell function, monocyte recruitment, and macrophage activity within the tumor microenvironment. Then, review recent literature to determine if these biomarkers reliably correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His transcriptomic profile from a kidney biopsy of the tumor's immune microenvironment reveals a tumor mutation burden of 6.0. Given these findings, is there evidence to suggest that he would likely respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His transcriptomic profile from a kidney biopsy of the tumor's immune microenvironment reveals a tumor mutation burden of 6.0. Given these findings, is there evidence to suggest that he would likely respond to Atezolizumab therapy? Review the gene expression data associated with T cell exhaustion, cytotoxic T cell activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, examine current literature to assess whether these biomarkers are consistently linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 22.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 22.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Please evaluate the gene expression data related to T cell exhaustion, cytotoxic T cell activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, review the current literature to determine if these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"I am evaluating a white male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment is available. Considering his tumor mutational burden is 1.0, could you provide insight into his potential response to Atezolizumab therapy?","I am evaluating a white male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment is available. Considering his tumor mutational burden is 1.0, could you provide insight into his potential response to Atezolizumab therapy? Review the gene expression data concerning T cell exhaustion, cytotoxic T cell activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a detailed literature review to determine whether these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"In a white female patient with bladder urothelial carcinoma, for whom a transcriptomic profile of the tumor immune microenvironment was obtained from a ureter biopsy and whose tumor mutational burden is not available (nan), would you anticipate a response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, for whom a transcriptomic profile of the tumor immune microenvironment was obtained from a ureter biopsy and whose tumor mutational burden is not available (nan), would you anticipate a response to Atezolizumab therapy? Examine the gene expression profiles associated with T cell exhaustion, cytotoxic T cell activity, monocyte recruitment, and macrophage function in the tumor microenvironment. Then, perform a comprehensive review of the scientific literature to evaluate whether these biomarkers are consistently correlated with favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"I have a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy yielding a transcriptomic profile of the tumor immune microenvironment. The tumor mutational burden is 2.0. Based on these findings, would Atezolizumab therapy be expected to be effective in this case?","I have a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy yielding a transcriptomic profile of the tumor immune microenvironment. The tumor mutational burden is 2.0. Based on these findings, would Atezolizumab therapy be expected to be effective in this case? Review the gene expression patterns associated with T cell exhaustion, cytotoxic T cell activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, systematically evaluate the scientific literature to determine whether these biomarkers reliably correlate with positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"My patient is a white male diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0. I have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on this data, what is the likelihood that he will respond to Atezolizumab therapy?","My patient is a white male diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0. I have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on this data, what is the likelihood that he will respond to Atezolizumab therapy? Examine the gene expression profiles related to T cell exhaustion, cytotoxic T cell activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a thorough review of the relevant scientific literature to assess whether these biomarkers consistently serve as predictors of positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"I have a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy yielded a transcriptomic profile of the tumor immune microenvironment. With a tumor mutational burden of 9.0, what is the likelihood that he will respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy yielded a transcriptomic profile of the tumor immune microenvironment. With a tumor mutational burden of 9.0, what is the likelihood that he will respond to atezolizumab therapy? Review the gene expression patterns associated with T cell exhaustion, cytotoxic T cell activity, monocyte recruitment, and macrophage function in the tumor microenvironment. Then, thoroughly examine the scientific literature to determine if these biomarkers reliably predict favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"I’m managing a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was analyzed using transcriptomic profiling from a kidney biopsy. The tumor mutation burden (TMB) is currently unavailable. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I’m managing a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was analyzed using transcriptomic profiling from a kidney biopsy. The tumor mutation burden (TMB) is currently unavailable. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Examine gene expression profiles related to T cell exhaustion, cytotoxic T cell function, monocyte recruitment, and macrophage activity in the tumor microenvironment. Then, conduct a comprehensive review of the scientific literature to assess whether these biomarkers consistently predict positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"I am treating a Caucasian male patient with bladder urothelial carcinoma and recently obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy. With a tumor mutation burden of 14.0, is this patient likely to respond favorably to Atezolizumab therapy?","I am treating a Caucasian male patient with bladder urothelial carcinoma and recently obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy. With a tumor mutation burden of 14.0, is this patient likely to respond favorably to Atezolizumab therapy? Review the expression levels of genes associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Following this, perform a thorough literature review to determine if these biomarkers reliably predict favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 18.0, what is the likelihood of response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 18.0, what is the likelihood of response to atezolizumab therapy? Evaluate the expression levels of genes linked to T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function in the tumor microenvironment. Then, conduct a comprehensive review of the literature to assess whether these biomarkers serve as reliable predictors of positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 13.0, with transcriptomic analysis performed on the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 13.0, with transcriptomic analysis performed on the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Assess the gene expression for markers associated with T cell exhaustion, cytotoxic function, monocyte recruitment, and macrophage activity in the tumor microenvironment. Then, perform a systematic review of the literature to determine whether these biomarkers reliably predict favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"I have a Black or African American female patient with bladder urothelial carcinoma who has a tumor mutation burden of 8.0, and I have obtained a transcriptomic profile of her tumor’s immune microenvironment from a bladder biopsy. Based on these findings, would you anticipate a response to Atezolizumab therapy?","I have a Black or African American female patient with bladder urothelial carcinoma who has a tumor mutation burden of 8.0, and I have obtained a transcriptomic profile of her tumor’s immune microenvironment from a bladder biopsy. Based on these findings, would you anticipate a response to Atezolizumab therapy? Evaluate the expression levels of genes linked to T cell exhaustion, cytotoxic function, monocyte recruitment, and macrophage activity within the tumor microenvironment. Then, conduct a systematic review of the current literature to determine if these biomarkers can reliably predict positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"In our white female patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 6.0. Can these findings help predict her likelihood of responding to atezolizumab therapy?","In our white female patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 6.0. Can these findings help predict her likelihood of responding to atezolizumab therapy? Assess the expression levels of genes associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, perform a systematic review of the current literature to determine whether these biomarkers can reliably predict favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) value is not available. Based on these findings, is the patient likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) value is not available. Based on these findings, is the patient likely to respond to atezolizumab therapy? Please quantify the expression of genes linked to T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Afterward, conduct a comprehensive literature review to evaluate whether these biomarkers can reliably predict positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 23.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he would respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 23.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he would respond favorably to Atezolizumab therapy? Please measure the expression levels of genes associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function in the tumor microenvironment. Then, perform a thorough literature review to determine if these biomarkers can consistently predict favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For a Caucasian female patient with bladder urothelial carcinoma, we have a transcriptomic profile of her tumor immune microenvironment obtained from a lymph node biopsy and a TMB value reported as not available. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, we have a transcriptomic profile of her tumor immune microenvironment obtained from a lymph node biopsy and a TMB value reported as not available. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy? Quantify the expression of genes involved in T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a comprehensive literature review to evaluate whether these biomarkers consistently predict favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"We have a white male patient with bladder urothelial carcinoma, and his tumor immune microenvironment has been characterized via transcriptomic profiling from a lymph node biopsy. With a tumor mutational burden of 2.0, what is the likelihood of a favorable response to atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma, and his tumor immune microenvironment has been characterized via transcriptomic profiling from a lymph node biopsy. With a tumor mutational burden of 2.0, what is the likelihood of a favorable response to atezolizumab therapy? Measure the expression levels of genes associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, perform a thorough literature review to determine if these biomarkers consistently correlate with positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"Given a white patient diagnosed with bladder urothelial carcinoma (BLCA), for whom a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed and the tumor mutational burden (TMB) is not available, would this patient be expected to respond to Atezolizumab therapy?","Given a white patient diagnosed with bladder urothelial carcinoma (BLCA), for whom a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed and the tumor mutational burden (TMB) is not available, would this patient be expected to respond to Atezolizumab therapy? Quantify gene expression for markers of T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a comprehensive literature review to assess whether these biomarkers consistently predict positive treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"A Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 7.0. Given the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, is Atezolizumab therapy likely to be effective in his case?","A Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 7.0. Given the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, is Atezolizumab therapy likely to be effective in his case? Measure the gene expression levels of biomarkers associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Following that, perform an extensive literature review to determine if these biomarkers are consistently linked with favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"Given my Asian male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic profile was obtained from a bladder biopsy and who has a tumor mutational burden of 1.0, are there clinically relevant indicators that suggest a likely response to atezolizumab therapy?","Given my Asian male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic profile was obtained from a bladder biopsy and who has a tumor mutational burden of 1.0, are there clinically relevant indicators that suggest a likely response to atezolizumab therapy? Evaluate the expression levels of genes related to T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a comprehensive review of the literature to assess whether these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a ureter biopsy and a TMB of 7.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a ureter biopsy and a TMB of 7.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Measure the gene expression profiles associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function in the tumor microenvironment. Next, systematically review the literature to determine if these biomarkers consistently correlate with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 5.0, based on the transcriptomic profile from the tumor immune microenvironment obtained via bladder biopsy, is there evidence to suggest that Atezolizumab would be an effective therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 5.0, based on the transcriptomic profile from the tumor immune microenvironment obtained via bladder biopsy, is there evidence to suggest that Atezolizumab would be an effective therapy? Evaluate the expression of genes linked to T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a systematic literature review to determine whether these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0. We obtained transcriptomic profiling data from his tumor immune microenvironment via bladder biopsy. Based on these findings, how likely is he to respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0. We obtained transcriptomic profiling data from his tumor immune microenvironment via bladder biopsy. Based on these findings, how likely is he to respond to atezolizumab therapy? Assess the expression of genes associated with T cell exhaustion, cytotoxic function, monocyte recruitment, and macrophage activity within the tumor microenvironment. Afterwards, perform a systematic literature review to determine if these biomarkers are consistently linked with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose lung biopsy provided a transcriptomic profile of the tumor immune microenvironment and whose tumor mutational burden is not available, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose lung biopsy provided a transcriptomic profile of the tumor immune microenvironment and whose tumor mutational burden is not available, what is the likelihood of a positive response to Atezolizumab therapy? Evaluate the expression levels of genes tied to T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a systematic literature review to determine whether these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy shows a tumor mutational burden of 2.0. Based on this information, what is the likelihood that the patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy shows a tumor mutational burden of 2.0. Based on this information, what is the likelihood that the patient will respond to atezolizumab therapy? Assess the expression levels of genes associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Following this, perform a systematic literature review to determine if these biomarkers are reliably linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"We have a White male patient with bladder urothelial carcinoma. The patient's tumor from bladder biopsy has been profiled transcriptomically to characterize the immune microenvironment, and the tumor mutational burden is 44.0. Based on these data, what is the likelihood that the patient will respond to atezolizumab therapy?","We have a White male patient with bladder urothelial carcinoma. The patient's tumor from bladder biopsy has been profiled transcriptomically to characterize the immune microenvironment, and the tumor mutational burden is 44.0. Based on these data, what is the likelihood that the patient will respond to atezolizumab therapy? Evaluate the levels of gene expression related to T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a systematic review of the literature to assess whether these biomarkers consistently correlate with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"In a White male patient with bladder urothelial carcinoma, given a tumor mutational burden of 15.0 and a transcriptomic analysis of the tumor immune microenvironment obtained from kidney biopsy, is there evidence to suggest that he would respond favorably to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, given a tumor mutational burden of 15.0 and a transcriptomic analysis of the tumor immune microenvironment obtained from kidney biopsy, is there evidence to suggest that he would respond favorably to Atezolizumab therapy? Analyze the expression levels of genes that indicate T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, perform a systematic literature review to determine if these biomarkers reliably predict improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"For a white male patient with bladder urothelial carcinoma (BLCA), whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 17 mutations/Mb, is there evidence to indicate a likely positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 17 mutations/Mb, is there evidence to indicate a likely positive response to atezolizumab therapy? Evaluate gene expression levels for markers indicative of T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a comprehensive systematic literature review to assess whether these biomarkers consistently predict improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained from kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained from kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Analyze the expression levels of genes associated with T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function in the tumor microenvironment. Next, perform a systematic review of the literature to determine if these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is not available (nan). Based on this information, is it likely that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is not available (nan). Based on this information, is it likely that he will respond to Atezolizumab therapy? Evaluate the gene expression profiles for markers of T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, conduct a systematic review of the literature to determine whether these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on this information, can we predict whether the patient will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on this information, can we predict whether the patient will respond to Atezolizumab therapy? Review the gene expression data for markers indicative of T cell exhaustion, cytotoxic function, monocyte recruitment, and macrophage activity within the tumor microenvironment. Then, systematically examine the current literature to assess whether these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"In a white patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 12.0, can we anticipate a favorable response to atezolizumab therapy?","In a white patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 12.0, can we anticipate a favorable response to atezolizumab therapy? Examine gene expression profiles for markers related to T cell exhaustion, cytotoxic function, monocyte recruitment, and macrophage activity in the tumor microenvironment. Then, review the current literature to determine whether these biomarkers are consistently associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment, obtained from a bladder biopsy, shows a tumor mutational burden of 6.0. Based on these findings, is there evidence to suggest that he will respond favorably to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment, obtained from a bladder biopsy, shows a tumor mutational burden of 6.0. Based on these findings, is there evidence to suggest that he will respond favorably to Atezolizumab therapy? Review gene expression profiles focusing on markers of T cell exhaustion, cytotoxic function, monocyte recruitment, and macrophage activity within the tumor microenvironment. Then, evaluate recent literature to determine if these biomarkers uniformly predict improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"My white male patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile available from his tumor immune microenvironment based on a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, should I expect a favorable response to Atezolizumab therapy?","My white male patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile available from his tumor immune microenvironment based on a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, should I expect a favorable response to Atezolizumab therapy? Examine the gene expression data for indicators of T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, review recent studies to determine if these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, does the transcriptomic profile of the tumor immune microenvironment obtained from a nano-biopsy suggest a likely positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, does the transcriptomic profile of the tumor immune microenvironment obtained from a nano-biopsy suggest a likely positive response to Atezolizumab therapy? Review the gene expression profiles to identify markers of T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, consult recent literature to determine if these biomarkers are consistently linked with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"My white male patient has bladder urothelial carcinoma, and his tumor’s transcriptomic profile of the immune microenvironment from a bladder biopsy shows a tumor mutational burden of 8.0. Based on these findings, is Atezolizumab therapy likely to be effective for him?","My white male patient has bladder urothelial carcinoma, and his tumor’s transcriptomic profile of the immune microenvironment from a bladder biopsy shows a tumor mutational burden of 8.0. Based on these findings, is Atezolizumab therapy likely to be effective for him? Examine the gene expression data to identify markers indicative of T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function within the tumor microenvironment. Then, review the latest research to determine if these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"A patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 0.0. Based on these findings, is a favorable response to atezolizumab therapy expected?","A patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 0.0. Based on these findings, is a favorable response to atezolizumab therapy expected? Review the gene expression profiles to detect markers of T cell exhaustion, cytotoxic activity, monocyte recruitment, and macrophage function in the tumor microenvironment. Then, consult the latest research to verify whether these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutation burden of 5.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutation burden of 5.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Examine gene expression data to identify signs of T cell exhaustion, cytotoxic function, monocyte recruitment, and macrophage activity within the tumor microenvironment. Then, review recent research to determine if these biomarkers are reliably associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 6.0, and transcriptomic profiling of his tumor immune microenvironment was performed on kidney biopsy tissue. Based on these findings, can we anticipate a favorable response to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 6.0, and transcriptomic profiling of his tumor immune microenvironment was performed on kidney biopsy tissue. Based on these findings, can we anticipate a favorable response to atezolizumab therapy? Review the gene expression profiles to detect indicators of T cell exhaustion, cytotoxic activity, monocyte infiltration, and macrophage function within the tumor microenvironment. Then, consult the latest research to evaluate whether these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"I have a white female patient with bladder urothelial carcinoma. We recently obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, but the tumor mutational burden (TMB) could not be determined. Based on this data, what is the likelihood that she will respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. We recently obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, but the tumor mutational burden (TMB) could not be determined. Based on this data, what is the likelihood that she will respond to Atezolizumab therapy? Examine the gene expression profiles to identify markers of T cell exhaustion, cytotoxic activity, monocyte infiltration, and macrophage function within the tumor microenvironment. After gathering this data, review current literature to determine if these biomarkers are consistently associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"In a white male patient with bladder urothelial carcinoma (BLCA) whose ureter biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden (TMB) of 59.0, what is the likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) whose ureter biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden (TMB) of 59.0, what is the likelihood of response to Atezolizumab therapy? Review the gene expression data to detect indicators of T cell exhaustion, cytotoxic potential, monocyte infiltration, and macrophage activity in the tumor microenvironment. Then, consult the latest research to assess whether these biomarkers reliably correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"In a white male patient with bladder urothelial carcinoma exhibiting a tumor mutational burden of 13.0 and available transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma exhibiting a tumor mutational burden of 13.0 and available transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of response to atezolizumab therapy? Examine the gene expression data to identify signs of T cell exhaustion, cytotoxic activity, as well as the presence of monocytes and macrophages within the tumor microenvironment. Then, review the latest scientific literature to determine if these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"We have a patient with bladder urothelial carcinoma whose ureter biopsy provided a transcriptomic profile of the tumor's immune microenvironment, and the tumor mutational burden is 12.0. Based on these findings, what is the expected likelihood of response to atezolizumab therapy?","We have a patient with bladder urothelial carcinoma whose ureter biopsy provided a transcriptomic profile of the tumor's immune microenvironment, and the tumor mutational burden is 12.0. Based on these findings, what is the expected likelihood of response to atezolizumab therapy? Analyze the gene expression data to detect markers of T cell exhaustion, evidence of cytotoxic activity, and the presence of monocytes and macrophages within the tumor microenvironment. Next, consult current peer-reviewed literature to determine whether these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 4.0, based on transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 4.0, based on transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Examine the gene expression profiles to identify markers of T cell exhaustion and cytotoxic activity, as well as the presence of monocytes and macrophages within the tumor microenvironment. Then, review recent peer-reviewed studies to evaluate whether these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor biopsy transcriptomic profile of the immune microenvironment indicates a Tumor Mutation Burden (TMB) of 11.0. Based on these results, is he likely to benefit from Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor biopsy transcriptomic profile of the immune microenvironment indicates a Tumor Mutation Burden (TMB) of 11.0. Based on these results, is he likely to benefit from Atezolizumab therapy? Review the gene expression data to pinpoint markers indicating T cell exhaustion and cytotoxic activity, as well as the levels of monocytes and macrophages within the tumor microenvironment. Following this, study recent peer-reviewed literature to determine if these biomarkers are reliably associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"My Caucasian patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 5.0, and we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, could we expect a favorable response to Atezolizumab therapy?","My Caucasian patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 5.0, and we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, could we expect a favorable response to Atezolizumab therapy? Please analyze the gene expression profiles to identify markers of T cell exhaustion and cytotoxic activity, along with assessing the abundance of monocytes and macrophages in the tumor microenvironment. After this analysis, review recent peer-reviewed studies to determine whether these biomarkers are consistently associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"I have a White female patient diagnosed with bladder urothelial carcinoma. We obtained transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, and her tumor mutation burden (TMB) is not available (nan). Based on this data, what is the likelihood that she will respond to Atezolizumab therapy?","I have a White female patient diagnosed with bladder urothelial carcinoma. We obtained transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, and her tumor mutation burden (TMB) is not available (nan). Based on this data, what is the likelihood that she will respond to Atezolizumab therapy? Review the gene expression data to identify indicators of T cell exhaustion and cytotoxic function, and quantify the presence of monocytes and macrophages in the tumor microenvironment. Then, examine recent peer-reviewed research to determine if these biomarkers are reliably linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, given that his tumor immune microenvironment transcriptomic profile (obtained via ureter biopsy) and a tumor mutational burden of 5.0 have been assessed, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, given that his tumor immune microenvironment transcriptomic profile (obtained via ureter biopsy) and a tumor mutational burden of 5.0 have been assessed, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please analyze the gene expression profiles to detect markers of T cell exhaustion and cytotoxic activity, and assess the levels of monocytes/macrophages in the tumor microenvironment. Then, consult recent peer-reviewed studies to evaluate whether these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"A native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma has a tumor mutation burden of 19.0 and available transcriptomic profiling of the tumor immune microenvironment from a prior biopsy. Based on these molecular characteristics, what is the likelihood that this patient will respond to Atezolizumab therapy?","A native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma has a tumor mutation burden of 19.0 and available transcriptomic profiling of the tumor immune microenvironment from a prior biopsy. Based on these molecular characteristics, what is the likelihood that this patient will respond to Atezolizumab therapy? Please evaluate gene expression data to identify markers indicative of T cell exhaustion and cytotoxic functions, and quantify the presence of monocytes/macrophages within the tumor microenvironment. Following this, review recent peer-reviewed literature to determine if these biomarkers are consistently associated with better treatment responses.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"I have a white male patient with bladder urothelial carcinoma whose bladder biopsy underwent transcriptomic profiling of the tumor immune microenvironment. The patient's tumor mutational burden is reported as indeterminate. Based on these findings, what can we expect regarding his potential response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose bladder biopsy underwent transcriptomic profiling of the tumor immune microenvironment. The patient's tumor mutational burden is reported as indeterminate. Based on these findings, what can we expect regarding his potential response to Atezolizumab therapy? Assess the gene expression profiles to identify markers related to T cell exhaustion and cytotoxic activity, and measure the levels of monocytes/macrophages within the tumor microenvironment. Then, review recent peer-reviewed literature to evaluate whether these biomarkers are reliably associated with improved treatment responses.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden (TMB) data is unavailable. Based on this information, how likely is the patient to respond to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden (TMB) data is unavailable. Based on this information, how likely is the patient to respond to Atezolizumab therapy? Evaluate the tumor sample's gene expression to identify markers that indicate T cell exhaustion and cytotoxic activity, and quantify the presence of monocytes/macrophages in the tumor microenvironment. Then, review recent peer-reviewed literature to determine if these biomarkers are consistently linked to improved treatment responses.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"In a white male patient with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy shows a tumor mutational burden of 33.0. Based on these findings, is there clinical evidence to support a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy shows a tumor mutational burden of 33.0. Based on these findings, is there clinical evidence to support a favorable response to atezolizumab therapy? Assess the tumor specimen by analyzing its gene expression profile to detect markers associated with T cell exhaustion and cytotoxic activity, and quantify the levels of monocytes/macrophages present within the tumor microenvironment. Subsequently, review current peer-reviewed studies to determine whether these biomarkers reliably correlate with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"A Caucasian male with bladder urothelial carcinoma has a high tumor mutational burden (32.0) and available transcriptomic profiling of his tumor immune microenvironment from a prior biopsy. Based on these observations, what is the likelihood that he would benefit from Atezolizumab therapy?","A Caucasian male with bladder urothelial carcinoma has a high tumor mutational burden (32.0) and available transcriptomic profiling of his tumor immune microenvironment from a prior biopsy. Based on these observations, what is the likelihood that he would benefit from Atezolizumab therapy? Evaluate the tumor sample by examining its gene expression profile for indicators of T cell exhaustion and cytotoxic function, and measure the proportion of monocytes/macrophages within its microenvironment. Then, consult current peer-reviewed literature to determine if these biomarkers consistently correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 2.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, can we predict his response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 2.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, can we predict his response to Atezolizumab therapy? Review the gene expression data from the tumor sample to identify markers of T cell exhaustion and cytotoxic function. Additionally, determine the percentage of monocytes and macrophages in the tumor microenvironment. After completing these analyses, consult up-to-date, peer-reviewed studies to evaluate whether these biomarkers are reliably associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"For a patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 14.0, how likely is a positive response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 14.0, how likely is a positive response to atezolizumab therapy? Examine the tumor sample’s gene expression data to detect markers of T cell exhaustion and indicators of cytotoxic function. Also, quantify the proportions of monocytes and macrophages in the tumor microenvironment. After completing these assessments, review current, peer-reviewed literature to determine if these biomarkers are consistently linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment via nan biopsy and recorded a tumor mutation burden (TMB) of nan. Based on these data, what is the likelihood that this patient will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment via nan biopsy and recorded a tumor mutation burden (TMB) of nan. Based on these data, what is the likelihood that this patient will respond to atezolizumab therapy? Please review the gene expression data from the tumor sample to identify markers of T cell exhaustion along with indicators of cytotoxic activity. Additionally, determine the percentages of monocytes and macrophages in the tumor microenvironment. Once you have completed these analyses, examine recent peer-reviewed studies to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"In a white male patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profiling indicates a tumor mutational burden of 9.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profiling indicates a tumor mutational burden of 9.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Review the gene expression data from the tumor sample to identify markers associated with T cell exhaustion and evidence of cytotoxic activity. Also, quantify the proportions of monocytes and macrophages present in the tumor microenvironment. After completing these analyses, consult recent peer-reviewed studies to determine if there is a correlation between these biomarkers and improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"For an Asian female patient with bladder urothelial carcinoma, a tumor mutational burden of 12, and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, how likely is it that she would respond to Atezolizumab therapy?","For an Asian female patient with bladder urothelial carcinoma, a tumor mutational burden of 12, and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, how likely is it that she would respond to Atezolizumab therapy? Examine the gene expression profile of the tumor sample to detect markers indicative of T cell exhaustion and cytotoxic activity. Additionally, quantify the relative abundance of monocytes and macrophages within the tumor microenvironment. Subsequently, review recent peer‐reviewed literature to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden (TMB) data is not available. Based on these findings, should I expect a favorable response to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden (TMB) data is not available. Based on these findings, should I expect a favorable response to atezolizumab therapy? Review the tumor sample's gene expression for indicators of T cell exhaustion and features of cytotoxic activity. Also, determine the relative proportions of monocytes and macrophages present in the tumor microenvironment. Finally, consult recent peer‐reviewed studies to evaluate if these biomarkers are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via transcriptomic profiling from a bladder biopsy and who has a TMB of 11.0, what is the likelihood of response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via transcriptomic profiling from a bladder biopsy and who has a TMB of 11.0, what is the likelihood of response to atezolizumab therapy? Examine the tumor sample for gene expression markers that indicate T cell exhaustion and cytotoxic activity. Additionally, quantify the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer‐reviewed literature to determine whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"My Caucasian male patient with bladder urothelial carcinoma has undergone a liver biopsy that provided a transcriptomic profile of the tumor immune microenvironment, and his tumor shows a mutational burden of 10.0 mutations per megabase. Given these findings, what is the likelihood that he will respond to atezolizumab therapy?","My Caucasian male patient with bladder urothelial carcinoma has undergone a liver biopsy that provided a transcriptomic profile of the tumor immune microenvironment, and his tumor shows a mutational burden of 10.0 mutations per megabase. Given these findings, what is the likelihood that he will respond to atezolizumab therapy? Evaluate the tumor sample for gene expression markers associated with T cell exhaustion and cytotoxic activity. Next, determine the relative proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review recent peer‐reviewed studies to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and his tumor mutation burden (TMB) is 12.0. What is the likelihood that he will respond favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and his tumor mutation burden (TMB) is 12.0. What is the likelihood that he will respond favorably to Atezolizumab therapy? Review the tumor specimen to identify gene expression profiles indicative of T cell exhaustion and cytotoxic function. Then, quantify the relative amounts of monocytes and macrophages within the tumor microenvironment. Finally, examine recent peer-reviewed literature to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"A patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 13.0. Based on this information, is there evidence to suggest that the patient would be responsive to atezolizumab therapy?","A patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 13.0. Based on this information, is there evidence to suggest that the patient would be responsive to atezolizumab therapy? Please examine the tumor specimen for gene expression patterns that suggest T cell exhaustion and the presence of cytotoxic functions. Next, measure the proportions of monocytes and macrophages within the tumor microenvironment. Finally, consult recent peer-reviewed studies to determine whether these biomarkers are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, given that the tumor immune microenvironment transcriptomic profile from a kidney biopsy shows a tumor mutational burden of 6.0, what is the likelihood of a favorable response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, given that the tumor immune microenvironment transcriptomic profile from a kidney biopsy shows a tumor mutational burden of 6.0, what is the likelihood of a favorable response to atezolizumab therapy? Review the tumor specimen to identify gene expression profiles indicating T cell exhaustion and cytotoxic activity. Next, quantify the relative presence of monocytes and macrophages in the tumor microenvironment. Finally, refer to recent peer-reviewed research to evaluate whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 21.0. We obtained transcriptomic data from the tumor immune microenvironment via a ureter biopsy. Based on this profile, can we predict his likelihood of responding to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 21.0. We obtained transcriptomic data from the tumor immune microenvironment via a ureter biopsy. Based on this profile, can we predict his likelihood of responding to Atezolizumab therapy? Examine the tumor sample to identify gene expression patterns that suggest T cell exhaustion and cytotoxic activity. Then, measure the relative proportions of monocytes and macrophages in the tumor microenvironment. Finally, review up-to-date peer-reviewed literature to determine if these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"For a Caucasian patient with bladder urothelial carcinoma, with a TMB of 14.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma, with a TMB of 14.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of response to Atezolizumab therapy? Review the tumor specimen to determine gene expression profiles that indicate both T cell exhaustion and cytotoxic activity. Next, quantify the percentages of monocytes and macrophages present in the tumor microenvironment. Finally, consult recent peer-reviewed studies to assess whether these biomarkers are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 9.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy is available. Based on this information, how likely is the patient to respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 9.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy is available. Based on this information, how likely is the patient to respond to atezolizumab therapy? Examine the tumor specimen to identify gene expression patterns that reflect both T cell exhaustion and cytotoxic activity. Then, determine the percentages of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed research to evaluate whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 27.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is it that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 27.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is it that he will respond to Atezolizumab therapy? Review the tumor specimen to detect gene expression patterns indicative of T cell exhaustion as well as cytotoxic activity. Next, calculate the proportions of monocytes and macrophages present in the tumor microenvironment. Finally, consult recent peer-reviewed literature to determine whether these biomarkers are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"I am managing a Caucasian female patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutational burden (TMB) value is unavailable (not reported). Based on these findings, can we predict whether she is likely to respond to Atezolizumab therapy?","I am managing a Caucasian female patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutational burden (TMB) value is unavailable (not reported). Based on these findings, can we predict whether she is likely to respond to Atezolizumab therapy? Examine the tumor specimen to identify gene expression profiles associated with T cell exhaustion and cytotoxic activity. Determine the relative proportions of monocytes and macrophages in the tumor microenvironment, and then review recent peer-reviewed studies to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"I have a white female patient with bladder urothelial carcinoma. The transcriptomic profile of her tumor immune microenvironment, obtained from a kidney biopsy, reveals a tumor mutation burden of 5.0. Based on these findings, is she likely to respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. The transcriptomic profile of her tumor immune microenvironment, obtained from a kidney biopsy, reveals a tumor mutation burden of 5.0. Based on these findings, is she likely to respond to Atezolizumab therapy? Analyze the tumor specimen to assess gene expression profiles that signal both T cell exhaustion and cytotoxic activity. Quantify the proportions of monocytes and macrophages within the tumor microenvironment. Finally, consult recent peer-reviewed studies to determine if these biomarkers are linked with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"My Caucasian male patient has bladder urothelial carcinoma, and I have a transcriptomic profile of his tumor immune microenvironment obtained via bladder biopsy. However, his tumor mutational burden data is unavailable. Based on these findings, how should we assess his likelihood of responding to Atezolizumab therapy?","My Caucasian male patient has bladder urothelial carcinoma, and I have a transcriptomic profile of his tumor immune microenvironment obtained via bladder biopsy. However, his tumor mutational burden data is unavailable. Based on these findings, how should we assess his likelihood of responding to Atezolizumab therapy? Examine the tumor specimen to identify gene expression patterns indicative of T cell exhaustion alongside markers of cytotoxic activity. Additionally, quantify the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed literature to determine whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"I have a white male patient with bladder urothelial carcinoma. His tumor biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 14.0. Based on these findings, should we anticipate a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. His tumor biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 14.0. Based on these findings, should we anticipate a favorable response to Atezolizumab therapy? Please evaluate the tumor specimen by assessing its gene expression profile for indicators of T cell exhaustion and markers of cytotoxic function. Additionally, determine the relative percentages of monocytes and macrophages present within the tumor microenvironment. Finally, review the most recent peer-reviewed studies to ascertain whether these biomarkers are linked to enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"A 65-year-old White male with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile available from a bladder biopsy and a tumor mutational burden (TMB) of 4.0. Based on this data, is he likely to respond to atezolizumab therapy?","A 65-year-old White male with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile available from a bladder biopsy and a tumor mutational burden (TMB) of 4.0. Based on this data, is he likely to respond to atezolizumab therapy? Please analyze the tumor specimen’s gene expression profile to identify markers of T cell exhaustion as well as indicators of cytotoxic function. Also, quantify the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the likelihood that he will respond to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the likelihood that he will respond to Atezolizumab therapy? Please review the tumor specimen’s gene expression data to identify markers indicative of T cell exhaustion and cytotoxic function. Quantify the relative amounts of monocytes and macrophages present in the tumor microenvironment. Additionally, consult recent peer-reviewed studies to assess whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"For my White female patient with bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 15.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 15.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy? Review the gene expression profile of the tumor specimen to detect markers that suggest T cell exhaustion as well as cytotoxic activity. In addition, determine the proportions of monocytes and macrophages within the tumor microenvironment. Finally, examine current, peer-reviewed literature to see if these biomarkers are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"My Caucasian male patient with bladder urothelial carcinoma has a TMB of 13.0. Based on the transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy?","My Caucasian male patient with bladder urothelial carcinoma has a TMB of 13.0. Based on the transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy? Examine the gene expression profile of the tumor sample to identify markers of T cell exhaustion and cytotoxic activity. Additionally, quantify the proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"A Caucasian female patient with bladder urothelial carcinoma has a tumor mutation burden of 14.0 and transcriptomic data characterizing the tumor immune microenvironment from her bladder biopsy. Based on these findings, is she likely to respond to Atezolizumab therapy?","A Caucasian female patient with bladder urothelial carcinoma has a tumor mutation burden of 14.0 and transcriptomic data characterizing the tumor immune microenvironment from her bladder biopsy. Based on these findings, is she likely to respond to Atezolizumab therapy? Review the gene expression data from the tumor sample to identify markers that indicate T cell exhaustion and cytotoxic activity. Next, determine the relative abundances of monocytes and macrophages within the tumor microenvironment. Finally, consult up-to-date, peer-reviewed literature to assess whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"In a Black/African American male patient with bladder urothelial carcinoma, the tumor transcriptomic profile and a tumor mutational burden of 17.0 have been characterized. Based on these findings, what is the likelihood of a clinical response to atezolizumab therapy?","In a Black/African American male patient with bladder urothelial carcinoma, the tumor transcriptomic profile and a tumor mutational burden of 17.0 have been characterized. Based on these findings, what is the likelihood of a clinical response to atezolizumab therapy? Examine the tumor’s gene expression data to identify markers indicative of T cell exhaustion and cytotoxic activity. Next, quantify the relative proportions of monocytes and macrophages within the tumor microenvironment. Finally, review current, peer-reviewed literature to determine if these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0, does the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy suggest a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0, does the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy suggest a favorable response to atezolizumab therapy? Review the tumor's gene expression data to pinpoint markers associated with T cell exhaustion and cytotoxic activity. Then, calculate the relative abundance of monocytes and macrophages in the tumor microenvironment. Finally, examine current peer-reviewed research to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"I have a white male patient with bladder urothelial carcinoma. Based on the tumor immune microenvironment transcriptomic profile obtained from the bladder biopsy and a tumor mutational burden (TMB) of 5.0, what is the likelihood that he may respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. Based on the tumor immune microenvironment transcriptomic profile obtained from the bladder biopsy and a tumor mutational burden (TMB) of 5.0, what is the likelihood that he may respond to Atezolizumab therapy? Examine the tumor's gene expression profile to identify markers indicative of T cell exhaustion and cytotoxic activity. Next, quantify the proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review the relevant peer-reviewed literature to determine whether these biomarkers are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"For a White male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 20.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a lung biopsy, what is the likelihood of achieving a response with Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 20.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a lung biopsy, what is the likelihood of achieving a response with Atezolizumab therapy? Evaluate the tumor’s gene expression profile to detect markers of T cell exhaustion as well as cytotoxic activity. Then, quantify the percentages of monocytes and macrophages within the tumor microenvironment. Finally, review peer-reviewed studies to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 3.0. Based on the transcriptomic profiling of his tumor’s immune microenvironment obtained from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 3.0. Based on the transcriptomic profiling of his tumor’s immune microenvironment obtained from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy? Conduct a gene expression analysis of the tumor to identify markers for both T cell exhaustion and cytotoxic activity. Next, determine the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to evaluate whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"For a Black/African American male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment has been obtained from a lymph node biopsy, but the tumor mutation burden (TMB) is not available. Based on these findings, could the patient be expected to respond to atezolizumab therapy?","For a Black/African American male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment has been obtained from a lymph node biopsy, but the tumor mutation burden (TMB) is not available. Based on these findings, could the patient be expected to respond to atezolizumab therapy? Perform a gene expression analysis on the tumor to identify markers indicating T cell exhaustion and cytotoxic activity. Then, quantify the proportions of monocytes and macrophages present in the tumor microenvironment. Lastly, review the latest peer-reviewed research to assess whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, given that we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and lack available data on tumor mutational burden, how might these factors influence his potential response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, given that we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and lack available data on tumor mutational burden, how might these factors influence his potential response to Atezolizumab therapy? Please conduct a gene expression analysis on the tumor sample to detect markers that indicate T cell exhaustion and cytotoxic activity. Next, quantify the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review the most recent peer-reviewed literature to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"I have a white female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using a nanobiopsy transcriptomic analysis. With a tumor mutation burden of 8.0, what is her likelihood of responding to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using a nanobiopsy transcriptomic analysis. With a tumor mutation burden of 8.0, what is her likelihood of responding to Atezolizumab therapy? Please perform a gene expression analysis on the tumor sample to identify markers for T cell exhaustion and cytotoxic activity. Then, quantify the proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review current peer-reviewed literature to assess whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile obtained from a kidney biopsy shows a tumor mutational burden of 6.0, what is the likelihood of response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile obtained from a kidney biopsy shows a tumor mutational burden of 6.0, what is the likelihood of response to atezolizumab therapy? Please conduct a gene expression profiling of the tumor sample to identify markers associated with T cell exhaustion as well as cytotoxic activity. Next, determine the relative abundance of monocytes and macrophages in the tumor microenvironment. Lastly, review current peer-reviewed literature to evaluate whether these biomarkers are correlated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,This patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 17.0. Could you provide your assessment on whether Atezolizumab therapy would be an effective treatment option?,"This patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 17.0. Could you provide your assessment on whether Atezolizumab therapy would be an effective treatment option? Please begin by performing gene expression profiling on the tumor sample to detect markers indicative of T cell exhaustion and cytotoxic activity. Next, quantify the relative proportions of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed studies to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutational burden is 6.0. Based on these findings, is it likely that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutational burden is 6.0. Based on these findings, is it likely that he will respond to Atezolizumab therapy? Begin by conducting gene expression analysis on the tumor sample to identify markers of T cell exhaustion and cytotoxic activity. Next, determine the relative proportions of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer‐reviewed studies to assess whether these biomarkers are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"For our white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 1.0 and transcriptomic profiling of the immune microenvironment from a lymph node biopsy, how likely is he to respond to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 1.0 and transcriptomic profiling of the immune microenvironment from a lymph node biopsy, how likely is he to respond to Atezolizumab therapy? First, perform gene expression analysis on the tumor sample to identify markers of T cell exhaustion and indicators of cytotoxic activity. Next, quantify the proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"For our white male patient with bladder urothelial carcinoma, we have transcriptomic data of the tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutational burden is not assessable. Based on this information, is there evidence to support the likelihood of a response to atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, we have transcriptomic data of the tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutational burden is not assessable. Based on this information, is there evidence to support the likelihood of a response to atezolizumab therapy? Begin by analyzing gene expression in the tumor sample to detect markers of T cell exhaustion and evidence of cytotoxic activity. Then, calculate the relative percentages of monocytes and macrophages within the tumor microenvironment. Finally, consult the latest peer-reviewed studies to determine whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"In a white female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a TMB of 7.0, would she be expected to respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a TMB of 7.0, would she be expected to respond to Atezolizumab therapy? First, perform a detailed gene expression analysis on the tumor sample to identify markers indicative of T cell exhaustion and to assess any signatures of cytotoxic activity. Next, determine the proportions of monocytes and macrophages present within the tumor microenvironment. Finally, review the most recent peer-reviewed literature to evaluate whether these specific biomarkers correlate with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"I have a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 21.0. Based on the transcriptomic profiling of her tumor immune microenvironment obtained from a bladder biopsy, can we expect a favorable response to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 21.0. Based on the transcriptomic profiling of her tumor immune microenvironment obtained from a bladder biopsy, can we expect a favorable response to Atezolizumab therapy? Begin by conducting an in-depth gene expression analysis of the tumor sample to detect markers of T cell exhaustion and any signatures of cytotoxic activity. Then, accurately quantify the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed studies to determine whether these specific biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutation burden of 7.0 and a transcriptomic profile available from a ureter biopsy detailing the tumor immune microenvironment. Based on these findings, is he likely to benefit from Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutation burden of 7.0 and a transcriptomic profile available from a ureter biopsy detailing the tumor immune microenvironment. Based on these findings, is he likely to benefit from Atezolizumab therapy? First, perform a detailed gene expression analysis on the tumor sample to identify markers of T cell exhaustion and evidence of cytotoxic activity. Next, precisely measure the ratios of monocytes and macrophages present in the tumor microenvironment. Finally, consult the latest peer-reviewed literature to assess whether these specific biomarkers are correlated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor has a TMB of 6.0 and transcriptomic profiling of the immune microenvironment obtained via lung biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor has a TMB of 6.0 and transcriptomic profiling of the immune microenvironment obtained via lung biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Begin by conducting an in-depth gene expression profiling of the tumor sample to identify indicators of T cell exhaustion and signs of cytotoxic activity. Next, accurately quantify the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed research to determine if these specific biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 6.0 has had a transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy. Based on these findings, do you expect the patient to respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 6.0 has had a transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy. Based on these findings, do you expect the patient to respond to Atezolizumab therapy? Start by performing a detailed gene expression analysis on the tumor sample to detect markers of T cell exhaustion and evidence of cytotoxic activity. Then, accurately measure the ratios of monocytes to macrophages in the tumor microenvironment. Finally, review current peer-reviewed studies to determine if these biomarkers are linked with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden is not available (reported as nan). Given these data, is there evidence to support a likely response to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden is not available (reported as nan). Given these data, is there evidence to support a likely response to atezolizumab therapy? Begin by conducting a comprehensive gene expression profile on the tumor sample to identify markers indicative of T cell exhaustion and signs of cytotoxic activity. Next, precisely determine the relative proportions of monocytes and macrophages within the tumor microenvironment. Finally, consult recent peer-reviewed literature to assess whether these biomarkers correlate with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, where the tumor immune microenvironment transcriptomic profile is available from a bladder biopsy and the tumor mutational burden is 3.0, would you expect a response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, where the tumor immune microenvironment transcriptomic profile is available from a bladder biopsy and the tumor mutational burden is 3.0, would you expect a response to Atezolizumab therapy? First, perform a detailed gene expression analysis on the tumor sample to pinpoint markers that indicate T cell exhaustion and active cytotoxic responses. Then, accurately quantify the proportions of monocytes and macrophages present within the tumor microenvironment. Finally, review current peer-reviewed literature to evaluate whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For my Asian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 5.0 mutations per megabase, what is the likelihood of response to Atezolizumab therapy?","For my Asian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 5.0 mutations per megabase, what is the likelihood of response to Atezolizumab therapy? Begin with a comprehensive gene expression analysis of the tumor sample to identify markers of T cell exhaustion and indicators of active cytotoxic responses. Next, accurately determine the percentages of monocytes and macrophages present within the tumor microenvironment. Finally, consult current peer-reviewed literature to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"A 64-year-old White male with urothelial carcinoma of the bladder has transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is not available. Based on these findings, would you expect him to respond to Atezolizumab therapy?","A 64-year-old White male with urothelial carcinoma of the bladder has transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is not available. Based on these findings, would you expect him to respond to Atezolizumab therapy? Perform a comprehensive gene expression analysis of the tumor sample to evaluate markers indicative of T cell exhaustion and active cytotoxic responses. Additionally, accurately quantify the proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review recent peer-reviewed literature to determine if these biomarkers are associated with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"For a Caucasian female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 12 mutations per megabase, is there evidence to suggest that she would respond favorably to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 12 mutations per megabase, is there evidence to suggest that she would respond favorably to atezolizumab therapy? Please perform a comprehensive gene expression profiling of the tumor sample to assess markers of T cell exhaustion and active cytotoxic responses. In addition, quantify the relative amounts of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine if these biomarkers are correlated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"A male Caucasian patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy. However, the tumor mutational burden is not available. Based on this information, can we anticipate whether the patient would respond to Atezolizumab therapy?","A male Caucasian patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy. However, the tumor mutational burden is not available. Based on this information, can we anticipate whether the patient would respond to Atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor tissue to evaluate markers associated with T cell exhaustion and active cytotoxic responses. Also, determine the proportions of monocytes and macrophages present within the tumor microenvironment. Finally, review recent peer-reviewed research to ascertain whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of her tumor immune microenvironment via bladder biopsy, and her tumor mutational burden is 5.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of her tumor immune microenvironment via bladder biopsy, and her tumor mutational burden is 5.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue. Specifically, assess markers indicative of T cell exhaustion as well as those reflecting active cytotoxic responses. In parallel, quantify the relative amounts of monocytes and macrophages within the tumor microenvironment. Finally, examine recent peer-reviewed studies to determine whether these biomarkers are associated with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden (TMB) of 4.0. Based on these findings, is he likely to benefit from Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden (TMB) of 4.0. Based on these findings, is he likely to benefit from Atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor specimen. Begin by evaluating markers associated with T cell exhaustion and those indicating active cytotoxic responses. Additionally, quantify the proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review recent peer-reviewed literature to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutation burden of 8.0, what is the expected likelihood of response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutation burden of 8.0, what is the expected likelihood of response to atezolizumab therapy? Please perform an in-depth gene expression analysis on the tumor sample. Start by assessing markers that indicate T cell exhaustion as well as those associated with active cytotoxic responses. Next, determine the relative percentages of monocytes and macrophages within the tumor’s microenvironment. Finally, review current peer-reviewed research to evaluate whether these biomarkers are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"For a white male patient with biopsy-confirmed bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of his tumor immune microenvironment available from a bladder biopsy, although his tumor mutational burden data is not available. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male patient with biopsy-confirmed bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of his tumor immune microenvironment available from a bladder biopsy, although his tumor mutational burden data is not available. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor specimen. Begin by evaluating markers indicative of T cell exhaustion alongside markers associated with active cytotoxic responses. Then, quantify the relative proportions of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For my African American male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 1.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is he to benefit from Atezolizumab therapy?","For my African American male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 1.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is he to benefit from Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor specimen. Start by assessing the expression levels of markers that indicate T cell exhaustion, as well as those associated with active cytotoxic responses. Next, determine the relative abundances of monocytes and macrophages in the tumor microenvironment. Finally, consult current peer-reviewed literature to evaluate whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, how should we interpret these findings in terms of predicting a response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, how should we interpret these findings in terms of predicting a response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample. Begin by quantifying the expression of markers that signal T cell exhaustion alongside those indicative of active cytotoxic responses. Then, assess the relative proportions of monocytes and macrophages present within the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample. Start by measuring the levels of markers associated with T cell exhaustion and those reflective of an active cytotoxic immune response. Next, determine the proportions of monocytes and macrophages within the tumor microenvironment. Finally, consult recent, peer-reviewed studies to evaluate whether these biomarkers correlate with favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"We have a white female patient with confirmed bladder urothelial carcinoma. The tumor's immune microenvironment transcriptomic profile from a bladder biopsy is available, and her tumor mutation burden is 7.0. Based on these findings, how likely is she to respond to atezolizumab therapy?","We have a white female patient with confirmed bladder urothelial carcinoma. The tumor's immune microenvironment transcriptomic profile from a bladder biopsy is available, and her tumor mutation burden is 7.0. Based on these findings, how likely is she to respond to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample. Begin by quantifying markers indicative of T cell exhaustion as well as markers that signal an active cytotoxic immune response. Then, assess the relative proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarkers are associated with favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have a white male patient with bladder urothelial carcinoma. We obtained the transcriptomic profile of his tumor's immune microenvironment from a previous biopsy, but his tumor mutational burden (TMB) is reported as “nan.” Based on these findings, how might we assess his likelihood of responding to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We obtained the transcriptomic profile of his tumor's immune microenvironment from a previous biopsy, but his tumor mutational burden (TMB) is reported as “nan.” Based on these findings, how might we assess his likelihood of responding to atezolizumab therapy? Please perform a detailed gene expression analysis of the tumor sample. Start by quantifying markers that indicate T cell exhaustion and those that reflect an active cytotoxic immune response. Next, evaluate the relative proportions of monocytes and macrophages within the tumor microenvironment. Finally, review the current peer-reviewed literature to determine whether these biomarkers are linked to favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please conduct an in-depth gene expression analysis of the tumor tissue. Begin by quantifying markers that signify T cell exhaustion and those that indicate an active cytotoxic immune response. Next, assess the relative frequencies of monocytes and macrophages in the tumor microenvironment. Finally, review the current peer-reviewed literature to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a lung biopsy and has a TMB of 8.0, can we expect a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a lung biopsy and has a TMB of 8.0, can we expect a favorable response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue. Start by quantifying markers associated with T cell exhaustion as well as those indicative of an active cytotoxic immune response. Next, determine the relative proportions of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"Given a white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","Given a white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Conduct a detailed gene expression analysis on the tumor tissue. Begin by quantifying biomarkers that indicate T cell exhaustion as well as those reflecting an active cytotoxic immune response. Then, evaluate the relative abundance of monocytes and macrophages in the tumor microenvironment. Finally, review relevant peer-reviewed studies to determine whether these biomarkers are linked to favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma who presents with a transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 13.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma who presents with a transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 13.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Perform a comprehensive gene expression profiling of the tumor tissue. Start by measuring biomarkers associated with T cell exhaustion alongside those that signal an active cytotoxic immune response. Next, assess the proportions of monocytes and macrophages within the tumor microenvironment. Lastly, consult current peer-reviewed literature to determine if these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 14.0 are available, is there evidence to suggest that Atezolizumab therapy would be an effective treatment option?","For an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 14.0 are available, is there evidence to suggest that Atezolizumab therapy would be an effective treatment option? Please perform a comprehensive gene expression analysis on the tumor tissue. Begin by quantifying biomarkers that indicate T cell exhaustion as well as those reflecting an active cytotoxic immune response. Next, evaluate the relative abundance of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to assess whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor transcriptomic profile was obtained via kidney biopsy, and his tumor mutation burden is 7.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor transcriptomic profile was obtained via kidney biopsy, and his tumor mutation burden is 7.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor tissue. Start by quantifying biomarkers that indicate T cell exhaustion and those that reflect an active cytotoxic immune response. Then, assess the relative levels of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine if these biomarkers are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"For a white patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile shows a tumor mutation burden (TMB) of 6.0, what is the likelihood of a positive response to atezolizumab therapy?","For a white patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile shows a tumor mutation burden (TMB) of 6.0, what is the likelihood of a positive response to atezolizumab therapy? Conduct a comprehensive gene expression analysis on the tumor tissue. Begin by quantifying biomarkers that signify T cell exhaustion as well as those indicating an active cytotoxic immune response. Next, determine the relative abundance of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed research to assess whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood that the patient will respond favorably to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood that the patient will respond favorably to atezolizumab therapy? Perform an in-depth gene expression profiling of the tumor sample. Begin by quantifying the biomarkers associated with T cell exhaustion and those indicative of an active cytotoxic immune response. Next, evaluate the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review the current peer-reviewed literature to determine whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 5.0, where transcriptomic profiling of the bladder biopsy reveals the tumor immune microenvironment, is there a likelihood of response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 5.0, where transcriptomic profiling of the bladder biopsy reveals the tumor immune microenvironment, is there a likelihood of response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample. Begin by measuring biomarkers that indicate T cell exhaustion as well as those that reflect an active cytotoxic immune response. Then, assess the relative abundance of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine if these biomarkers are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"I have a white male patient with bladder urothelial carcinoma whose bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment. His tumor mutation burden is 49.0. Based on these findings, is he likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment. His tumor mutation burden is 49.0. Based on these findings, is he likely to respond to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor tissue. Start by quantifying biomarkers that signify T cell exhaustion as well as those indicating an active cytotoxic immune response. Next, determine the relative proportions of monocytes and macrophages present in the tumor microenvironment. Finally, review the most recent peer-reviewed literature to evaluate whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) presents with a tumor mutation burden (TMB) of 12.0, and we have transcriptomic data from the tumor immune microenvironment obtained via a bladder biopsy. Based on this information, what is the likelihood that he would respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma (BLCA) presents with a tumor mutation burden (TMB) of 12.0, and we have transcriptomic data from the tumor immune microenvironment obtained via a bladder biopsy. Based on this information, what is the likelihood that he would respond to atezolizumab therapy? Perform a comprehensive gene expression analysis on the tumor tissue. Begin by quantifying biomarkers that indicate T cell exhaustion and those that reflect an active cytotoxic immune response. Next, assess the proportions of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed research to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"My Caucasian male patient has bladder urothelial carcinoma, and we have obtained transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. However, his tumor mutation burden (TMB) data is not available (reported as nan). Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","My Caucasian male patient has bladder urothelial carcinoma, and we have obtained transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. However, his tumor mutation burden (TMB) data is not available (reported as nan). Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Conduct a detailed gene expression analysis of the tumor tissue. First, measure biomarkers associated with T cell exhaustion alongside those indicating an active cytotoxic immune response. Then, quantify the relative amounts of monocytes and macrophages present within the tumor microenvironment. Finally, review recent peer-reviewed studies to assess whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, is there evidence to suggest that Atezolizumab therapy would be effective?","For a white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, is there evidence to suggest that Atezolizumab therapy would be effective? Please perform an in-depth gene expression analysis on the tumor tissue. Begin by assessing biomarkers that indicate T cell exhaustion as well as those that show an active cytotoxic immune response. Next, determine the relative proportions of monocytes and macrophages in the tumor microenvironment. Finally, review recent, peer-reviewed literature to evaluate if these biomarkers are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For my Black or African American male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy shows a tumor mutation burden of 11.0, what is the likelihood that he will respond to Atezolizumab therapy?","For my Black or African American male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy shows a tumor mutation burden of 11.0, what is the likelihood that he will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor tissue. Start by quantifying biomarkers associated with T cell exhaustion as well as those indicative of a robust cytotoxic immune response. Then, evaluate the tumor microenvironment by determining the relative proportions of monocytes and macrophages. Finally, review current, peer-reviewed literature to determine whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed and tumor mutation burden data is unavailable, what is the anticipated response to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed and tumor mutation burden data is unavailable, what is the anticipated response to atezolizumab therapy? Please perform a detailed gene expression profile of the tumor tissue. Begin by measuring biomarkers that indicate T cell exhaustion as well as those associated with a strong cytotoxic immune response. Also, assess the tumor microenvironment by quantifying the relative numbers of monocytes and macrophages. Lastly, examine the latest peer-reviewed research to determine if these biomarkers are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) and available transcriptomic data from a ureter biopsy of the tumor immune microenvironment. Given that the tumor mutational burden (TMB) is not available, how might this affect his potential response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) and available transcriptomic data from a ureter biopsy of the tumor immune microenvironment. Given that the tumor mutational burden (TMB) is not available, how might this affect his potential response to Atezolizumab therapy? Please conduct comprehensive gene expression profiling on the tumor tissue. Begin by quantifying biomarkers that signal T cell exhaustion and those indicative of a strong cytotoxic immune response. Additionally, evaluate the tumor microenvironment by determining the relative proportions of monocytes and macrophages. Finally, review recent peer-reviewed studies to assess whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who presents with a tumor mutational burden of 17.0. Based on the transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, is there evidence to support a likely response to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who presents with a tumor mutational burden of 17.0. Based on the transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, is there evidence to support a likely response to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample. Start by measuring biomarkers associated with T cell exhaustion as well as those linked to a strong cytotoxic immune response. Next, assess the tumor microenvironment by quantifying the relative amounts of monocytes and macrophages. Lastly, review recent peer-reviewed literature to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 22.0 and available transcriptomic profiling of the tumor immune microenvironment, how should we interpret these findings in terms of likelihood of response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 22.0 and available transcriptomic profiling of the tumor immune microenvironment, how should we interpret these findings in terms of likelihood of response to atezolizumab therapy? Please conduct a comprehensive gene expression evaluation of the tumor sample. Begin by quantifying biomarkers that indicate T cell exhaustion alongside those reflective of a robust cytotoxic immune response. Then, evaluate the tumor microenvironment by determining the relative proportions of monocytes and macrophages. Finally, review recent peer-reviewed research to assess whether these biomarkers are correlated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the reported tumor mutation burden (TMB) is noted as “nan.” Based on these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the reported tumor mutation burden (TMB) is noted as “nan.” Based on these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample. Start by quantifying biomarkers that indicate T cell exhaustion as well as those that reflect a strong cytotoxic immune response. Next, assess the tumor microenvironment by measuring the relative levels of monocytes and macrophages. Finally, consult recent peer-reviewed literature to determine if these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"For a patient with bladder urothelial carcinoma who has undergone kidney biopsy with transcriptomic profiling of the tumor immune microenvironment and has a tumor mutation burden of 18.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has undergone kidney biopsy with transcriptomic profiling of the tumor immune microenvironment and has a tumor mutation burden of 18.0, what is the likelihood of a favorable response to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample. Begin by quantifying biomarkers that signal T cell exhaustion and those that are indicative of a robust cytotoxic immune response. Then, evaluate the tumor microenvironment by measuring the relative abundance of monocytes and macrophages. Finally, review current peer-reviewed literature to verify whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"I have a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment. Given his tumor mutational burden of 5.0, should we expect a favorable response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of his tumor immune microenvironment. Given his tumor mutational burden of 5.0, should we expect a favorable response to atezolizumab therapy? Conduct a detailed gene expression analysis of the tumor specimen. First, quantify biomarkers that are indicative of T cell exhaustion as well as those that reflect an active cytotoxic immune response. Next, assess the tumor microenvironment by measuring the relative levels of monocytes and macrophages. Lastly, review up-to-date, peer-reviewed studies to determine whether these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"My white male patient has bladder urothelial carcinoma (BLCA) with a tumor mutation burden of 4.0. I also have transcriptomic data of the tumor immune microenvironment from a bladder biopsy. Based on these findings, how likely is this patient to benefit from atezolizumab therapy?","My white male patient has bladder urothelial carcinoma (BLCA) with a tumor mutation burden of 4.0. I also have transcriptomic data of the tumor immune microenvironment from a bladder biopsy. Based on these findings, how likely is this patient to benefit from atezolizumab therapy? Perform a comprehensive gene expression analysis on the tumor sample. Begin by quantifying biomarkers associated with T cell exhaustion along with those that signify an active cytotoxic immune response. Then, evaluate the tumor microenvironment by determining the relative abundance of monocytes and macrophages. Finally, review current peer-reviewed literature to assess whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 5.0, and transcriptomic data from the tumor immune microenvironment obtained via kidney biopsy, is there evidence to support a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 5.0, and transcriptomic data from the tumor immune microenvironment obtained via kidney biopsy, is there evidence to support a favorable response to Atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor sample. First, measure the levels of biomarkers that indicate both T cell exhaustion and an active cytotoxic immune response. Next, assess the tumor microenvironment by quantifying the presence of monocytes and macrophages. Finally, review current, peer-reviewed research to determine whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) presenting a tumor mutational burden of 12.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that Atezolizumab therapy would be effective?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) presenting a tumor mutational burden of 12.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that Atezolizumab therapy would be effective? Please perform a comprehensive gene expression analysis on the tumor tissue. Start by quantifying the biomarkers that indicate T cell exhaustion and active cytotoxic immune responses. Then, evaluate the tumor microenvironment by measuring the levels of monocytes and macrophages. Finally, review current, peer-reviewed research to determine whether these biomarkers are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), how might the transcriptomic profile of the tumor immune microenvironment from a liver biopsy inform the likelihood of response to atezolizumab therapy, especially given the absence of tumor mutational burden (TMB) data?","In a white male patient with bladder urothelial carcinoma (BLCA), how might the transcriptomic profile of the tumor immune microenvironment from a liver biopsy inform the likelihood of response to atezolizumab therapy, especially given the absence of tumor mutational burden (TMB) data? Conduct a comprehensive gene expression analysis on the tumor tissue. Begin by quantifying biomarkers that reflect T cell exhaustion and active cytotoxic immune responses. Next, assess the tumor microenvironment by measuring the levels of monocytes and macrophages. Finally, review current peer-reviewed literature to evaluate whether these biomarkers are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"In a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, but the tumor mutational burden is not assessable (TMB data unavailable). Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, but the tumor mutational burden is not assessable (TMB data unavailable). Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy? Perform a detailed gene expression analysis on the tumor sample. First, quantify biomarkers indicative of T cell exhaustion along with those reflecting active cytotoxic responses. Then, evaluate the tumor microenvironment by measuring levels of monocytes and macrophages. Finally, review current peer-reviewed studies to determine if these biomarkers correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. We obtained transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 10. Would you consider atezolizumab a likely effective treatment option for him?","I have a Caucasian male patient with bladder urothelial carcinoma. We obtained transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 10. Would you consider atezolizumab a likely effective treatment option for him? Analyze the gene expression profile of the tumor sample in detail. Begin by measuring biomarkers that indicate T cell exhaustion as well as those that reflect active cytotoxic responses. Next, assess the tumor microenvironment by quantifying the levels of monocytes and macrophages. Finally, review relevant current peer-reviewed literature to determine whether these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"For a white female patient with bladder urothelial carcinoma, given a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 6.0, what are the prospects for a therapeutic response to atezolizumab?","For a white female patient with bladder urothelial carcinoma, given a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 6.0, what are the prospects for a therapeutic response to atezolizumab? Please perform a comprehensive analysis of the tumor's gene expression. Start by quantifying biomarkers that indicate T cell exhaustion and those signaling active cytotoxic responses. Then, evaluate the tumor microenvironment by measuring the presence of monocytes and macrophages. Finally, consult current peer-reviewed research to determine if these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutation burden (TMB) result was not available. Based on these findings, what is the likelihood that she would respond to atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutation burden (TMB) result was not available. Based on these findings, what is the likelihood that she would respond to atezolizumab therapy? Conduct a thorough evaluation of the tumor’s gene expression profile. Begin by measuring the levels of biomarkers associated with T cell exhaustion as well as those that indicate active cytotoxic responses. Next, assess the tumor microenvironment by quantifying the presence of monocytes and macrophages. Finally, review up-to-date, peer-reviewed research to determine whether these biomarker patterns are correlated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"The patient is a white female with bladder urothelial carcinoma. Her transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 15 have been evaluated. Based on this data, what is the likelihood that she will respond to Atezolizumab therapy?","The patient is a white female with bladder urothelial carcinoma. Her transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 15 have been evaluated. Based on this data, what is the likelihood that she will respond to Atezolizumab therapy? Perform a comprehensive analysis of the tumor's gene expression profile. Start by quantifying biomarkers indicative of T cell exhaustion alongside those corresponding to active cytotoxic responses. Then, evaluate the tumor microenvironment by measuring the levels of monocytes and macrophages. Finally, review current peer-reviewed research to determine if these biomarker patterns are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, a tumor mutational burden of 8.0, and transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, a tumor mutational burden of 8.0, and transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please conduct a detailed evaluation of the tumor’s gene expression profile. Begin by quantifying biomarkers that indicate T cell exhaustion as well as those reflecting active cytotoxic responses. Next, assess the tumor microenvironment by measuring the presence of monocytes and macrophages. Finally, review the latest peer-reviewed literature to determine if these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. The patient's transcriptomic profile of the tumor immune microenvironment was obtained from a bladder biopsy, and his tumor mutation burden is 6.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. The patient's transcriptomic profile of the tumor immune microenvironment was obtained from a bladder biopsy, and his tumor mutation burden is 6.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Please perform a comprehensive assessment of the tumor's gene expression profile. First, quantify biomarkers that serve as indicators of T cell exhaustion and markers that signify active cytotoxic responses. Then, evaluate the tumor microenvironment by quantifying the levels of monocytes and macrophages present. Finally, review the most recent peer-reviewed publications to determine if these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"I have a white male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profile of the tumor immune microenvironment, obtained via bladder biopsy, shows a tumor mutation burden (TMB) of 19. Based on these findings, is he likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profile of the tumor immune microenvironment, obtained via bladder biopsy, shows a tumor mutation burden (TMB) of 19. Based on these findings, is he likely to respond to atezolizumab therapy? Conduct a thorough analysis of the tumor's gene expression profile. Begin by quantifying biomarkers that indicate T cell exhaustion alongside those reflecting active cytotoxic responses. Next, evaluate the tumor microenvironment by measuring the levels of monocytes and macrophages. Finally, review the latest peer-reviewed literature to determine if these biomarker profiles are linked with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"I am managing a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 12.0. We have also obtained a transcriptomic profile of his tumor immune microenvironment from a previous biopsy. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I am managing a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 12.0. We have also obtained a transcriptomic profile of his tumor immune microenvironment from a previous biopsy. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Evaluate the tumor's gene expression profile comprehensively. Start by measuring biomarkers that signal T cell exhaustion as well as those indicative of active cytotoxic responses. Then, assess the tumor microenvironment by quantifying monocyte and macrophage populations. Finally, consult the latest peer-reviewed studies to see if these biomarker patterns are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"A Caucasian patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is not available. Given these details, can we expect the patient to respond to atezolizumab therapy?","A Caucasian patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is not available. Given these details, can we expect the patient to respond to atezolizumab therapy? Thoroughly assess the tumor's gene expression profile by beginning with the measurement of biomarkers that indicate T cell exhaustion and those that reflect active cytotoxic responses. Next, evaluate the tumor microenvironment by quantifying the populations of monocytes and macrophages. Finally, review the most recent peer-reviewed studies to determine whether these biomarker patterns correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"In a Caucasian patient with bladder urothelial carcinoma and a tumor mutational burden of 3.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma and a tumor mutational burden of 3.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Begin by evaluating the tumor’s gene expression profile with an initial focus on biomarkers indicative of T cell exhaustion alongside those that signal active cytotoxic responses. Subsequently, analyze the tumor microenvironment by quantifying the levels of monocytes and macrophages. Finally, review current peer-reviewed literature to verify whether these biomarker profiles are associated with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"In a Caucasian patient with bladder urothelial carcinoma, a tumor mutational burden of 18, and transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the anticipated response to atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma, a tumor mutational burden of 18, and transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the anticipated response to atezolizumab therapy? Start by assessing the tumor’s gene expression, emphasizing biomarkers that indicate T cell exhaustion as well as those that reflect active cytotoxic function. Then, examine the tumor microenvironment by measuring monocyte and macrophage levels. Finally, consult recent peer-reviewed literature to determine if these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"For a white male patient with bladder urothelial carcinoma, whose kidney biopsy analysis of the tumor immune microenvironment shows a tumor mutational burden of 15.0, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose kidney biopsy analysis of the tumor immune microenvironment shows a tumor mutational burden of 15.0, what is the likelihood that he will respond to Atezolizumab therapy? Begin by evaluating the tumor’s gene expression profile, specifically identifying biomarkers that signal T cell exhaustion alongside those that indicate active cytotoxic activity. Next, assess the tumor microenvironment by quantifying monocyte and macrophage populations. Finally, review up-to-date, peer-reviewed studies to ascertain if these biomarker patterns are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutational burden (TMB) data are unavailable. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutational burden (TMB) data are unavailable. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy? Step one: Analyze the tumor’s gene expression profile by identifying biomarkers that reflect T cell exhaustion as well as those indicating active cytotoxic responses. Next, quantify the monocyte and macrophage populations within the tumor microenvironment. Finally, consult recent, peer-reviewed literature to determine whether these biomarker profiles are associated with favorable treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"I have a White female patient with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutational burden (TMB) is not available. Based on this information, what is the likelihood that she will respond to Atezolizumab therapy?","I have a White female patient with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutational burden (TMB) is not available. Based on this information, what is the likelihood that she will respond to Atezolizumab therapy? First, review the tumor’s gene expression profile to identify biomarkers that indicate T cell exhaustion alongside those reflecting active cytotoxic responses. Next, measure the populations of monocytes and macrophages within the tumor microenvironment. Finally, consult up-to-date, peer-reviewed studies to assess whether these biomarker patterns are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"For my White male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, how likely is he to benefit from Atezolizumab therapy?","For my White male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, how likely is he to benefit from Atezolizumab therapy? Begin by evaluating the tumor's gene expression profile to detect biomarkers that are indicative of T cell exhaustion as well as those signaling active cytotoxic responses. Then, quantify the levels of monocytes and macrophages present in the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine if the identified biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"I have a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled using transcriptomics from a kidney biopsy. Her tumor mutational burden value is not available. Given this information, can we expect a favorable response to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled using transcriptomics from a kidney biopsy. Her tumor mutational burden value is not available. Given this information, can we expect a favorable response to Atezolizumab therapy? First, assess the tumor’s gene expression profile to identify biomarkers that indicate T cell exhaustion alongside those that signal active cytotoxic responses. Next, measure the density of monocytes and macrophages within the tumor microenvironment. Lastly, consult the latest peer-reviewed research to determine whether these biomarker patterns correlate with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have a Black/African American patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment was performed from a ureter biopsy, but the tumor mutation burden (TMB) is unavailable. Based on this information, is the patient likely to respond to atezolizumab therapy?","I have a Black/African American patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment was performed from a ureter biopsy, but the tumor mutation burden (TMB) is unavailable. Based on this information, is the patient likely to respond to atezolizumab therapy? Evaluate the tumor’s gene expression profile to identify biomarkers of both T cell exhaustion and active cytotoxic activity. Then, assess the concentration of monocytes and macrophages within the tumor microenvironment. Finally, review the most recent peer-reviewed literature to determine if these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, and her tumor mutation burden is reported as ""nan."" Based on these findings, should we expect her to respond favorably to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, and her tumor mutation burden is reported as ""nan."" Based on these findings, should we expect her to respond favorably to Atezolizumab therapy? Assess the tumor’s gene expression to identify markers indicating both T cell exhaustion and active cytotoxic function. Next, quantify the numbers of monocytes and macrophages in the tumor microenvironment. Finally, review the latest peer-reviewed studies to determine whether these biomarker patterns are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"I have a white male patient with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden of 4.0. Based on these findings, can we expect a favorable response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden of 4.0. Based on these findings, can we expect a favorable response to atezolizumab therapy? Evaluate the tumor's gene expression profile for markers that signal both T cell exhaustion and active cytotoxic activity. Then, quantify the populations of monocytes and macrophages within the tumor microenvironment. Finally, consult recent peer-reviewed literature to determine if these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 14.0, how predictive is this profile of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 14.0, how predictive is this profile of a favorable response to atezolizumab therapy? Assess the tumor’s gene expression profile to identify markers indicating T cell exhaustion as well as active cytotoxic function. Next, quantify the number of monocytes and macrophages present in the tumor microenvironment. Finally, review up-to-date, peer-reviewed research to determine whether these biomarker patterns correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment from a lung biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment from a lung biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor’s gene expression, paying close attention to markers that indicate T cell exhaustion and active cytotoxicity. Then, estimate the density of monocytes and macrophages within the tumor microenvironment. Finally, investigate current, peer-reviewed studies to determine if these biomarker patterns are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I have a white female patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment was performed using a lung biopsy sample, and her tumor mutational burden is 3.0 mutations/Mb. Based on these findings, is she likely to respond to atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment was performed using a lung biopsy sample, and her tumor mutational burden is 3.0 mutations/Mb. Based on these findings, is she likely to respond to atezolizumab therapy? Assess the tumor’s gene expression profile, focusing specifically on markers associated with T cell exhaustion and active cytotoxic responses. Next, quantify the presence of monocytes and macrophages in the tumor microenvironment. Finally, review up-to-date peer-reviewed research to determine whether these biomarker patterns correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"For my white male patient with bladder urothelial carcinoma and a tumor mutation burden of 11.0, the transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma and a tumor mutation burden of 11.0, the transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy? Begin by evaluating the tumor's gene expression profile, specifically examining markers indicative of T cell exhaustion as well as those reflecting active cytotoxic responses. Then, accurately quantify the number of monocytes and macrophages within the tumor microenvironment. Finally, consult the most recent peer-reviewed literature to determine if these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 4.0, based on the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, what is the anticipated response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 4.0, based on the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, what is the anticipated response to Atezolizumab therapy? First, review the tumor’s gene expression profile, paying particular attention to markers of T cell exhaustion and indicators of active cytotoxic responses. Next, accurately determine the counts of monocytes and macrophages in the tumor microenvironment. Finally, consult the latest peer-reviewed research to assess whether these biomarker patterns are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"In a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden data is not available. Based on this information, is Atezolizumab likely to be an effective treatment option?","In a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden data is not available. Based on this information, is Atezolizumab likely to be an effective treatment option? Begin by reviewing the tumor's gene expression profile, specifically examining markers that indicate T cell exhaustion and active cytotoxic responses. Next, accurately quantify the monocytes and macrophages present within the tumor microenvironment. Finally, consult the latest peer-reviewed studies to determine whether these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"A Caucasian patient with bladder urothelial carcinoma has had a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not available. How might this impact our assessment of their likelihood of responding to Atezolizumab therapy?","A Caucasian patient with bladder urothelial carcinoma has had a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not available. How might this impact our assessment of their likelihood of responding to Atezolizumab therapy? Start by examining the tumor's gene expression profile, paying particular attention to markers that suggest T cell exhaustion and active cytotoxic responses. Next, accurately measure the number of monocytes and macrophages present in the tumor microenvironment. Finally, review the most recent peer-reviewed literature to assess whether these biomarker patterns are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"I have a white male patient with bladder urothelial carcinoma whose tumor’s immune microenvironment has been characterized through transcriptomic profiling from a previous biopsy. With a TMB of 18.0, can his molecular profile help predict a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor’s immune microenvironment has been characterized through transcriptomic profiling from a previous biopsy. With a TMB of 18.0, can his molecular profile help predict a favorable response to Atezolizumab therapy? Begin by evaluating the tumor's gene expression profile, focusing on markers that indicate T cell exhaustion as well as active cytotoxic responses. Next, quantify the monocytes and macrophages within the tumor microenvironment. Finally, consult the most recent peer-reviewed research to determine if these biomarker patterns correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"I have a white male patient with bladder urothelial carcinoma whose bladder biopsy yielded a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 19.0. Based on these findings, is he likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose bladder biopsy yielded a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 19.0. Based on these findings, is he likely to respond to atezolizumab therapy? First, assess the tumor’s gene expression profile, concentrating on markers for T cell exhaustion and active cytotoxic responses. Then, determine the abundance of monocytes and macrophages in the tumor microenvironment. Finally, review the latest peer-reviewed research to establish if these biomarker patterns are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 35.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 35.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Evaluate the tumor’s gene expression profile with a focus on markers indicating T cell exhaustion and active cytotoxic responses. Next, quantify the levels of monocytes and macrophages in the tumor microenvironment. Finally, review recent peer-reviewed research to determine whether these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0. Using transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0. Using transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that he will respond favorably to Atezolizumab therapy? Review the tumor’s gene expression profile, paying particular attention to markers that indicate T cell exhaustion and signs of active cytotoxic responses. Then, determine the quantity of monocytes and macrophages present within the tumor microenvironment. Lastly, consult recent peer-reviewed studies to assess whether these biomarker patterns are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"My white male patient with bladder urothelial carcinoma has a tumor mutation burden of 5.0, and we have obtained transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy. Based on these findings, is it likely that he will respond to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma has a tumor mutation burden of 5.0, and we have obtained transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy. Based on these findings, is it likely that he will respond to Atezolizumab therapy? Examine the tumor's gene expression profile by identifying markers of T cell exhaustion and indicators of active cytotoxic responses. Quantify the number of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed studies to determine if these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed, and the tumor mutational burden is 16.0. Based on these findings, is this patient likely to respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed, and the tumor mutational burden is 16.0. Based on these findings, is this patient likely to respond to Atezolizumab therapy? Assess the tumor's gene expression to identify markers indicative of T cell exhaustion and signs of active cytotoxic activity. Additionally, measure the populations of monocytes and macrophages present in the tumor microenvironment. Finally, review current peer-reviewed literature to evaluate whether these biomarker profiles correlate with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"In a patient with bladder urothelial carcinoma, a TMB of 8.0, and transcriptomic profiling data of the tumor immune microenvironment from a bladder biopsy, what indicators should be evaluated to determine the likelihood of response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma, a TMB of 8.0, and transcriptomic profiling data of the tumor immune microenvironment from a bladder biopsy, what indicators should be evaluated to determine the likelihood of response to atezolizumab therapy? Evaluate the tumor's gene expression profile for markers of T cell exhaustion and indicators of active cytotoxic responses. Also, quantify the levels of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed studies to determine whether these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"I have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy of a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0. Based on these findings, could you clarify whether he is likely to respond to Atezolizumab therapy?","I have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy of a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0. Based on these findings, could you clarify whether he is likely to respond to Atezolizumab therapy? Assess the tumor's gene expression to identify markers indicative of T cell exhaustion and active cytotoxic responses. In addition, measure the number of monocytes and macrophages in the tumor microenvironment. Finally, review current peer-reviewed studies to determine if these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"For a Caucasian female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 5.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 5.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor's gene expression profile to identify biomarkers linked to T cell exhaustion and active cytotoxic responses. Additionally, quantify the monocyte and macrophage populations in the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"My Caucasian female patient with bladder urothelial carcinoma (BLCA) has a tumor mutation burden (TMB) of 7 and transcriptomic data available from her tumor immune microenvironment via bladder biopsy. Based on these findings, would you expect a favorable response to atezolizumab therapy?","My Caucasian female patient with bladder urothelial carcinoma (BLCA) has a tumor mutation burden (TMB) of 7 and transcriptomic data available from her tumor immune microenvironment via bladder biopsy. Based on these findings, would you expect a favorable response to atezolizumab therapy? Assess the tumor's gene expression data to identify biomarkers that indicate both T cell exhaustion and active cytotoxic T cell responses. Also, quantify the populations of monocytes and macrophages present in the tumor microenvironment. Finally, review the latest peer-reviewed research to determine whether these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not available. Based on the available data, how likely is this patient to respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not available. Based on the available data, how likely is this patient to respond to Atezolizumab therapy? Review the tumor’s gene expression data to pinpoint biomarkers that signal both T cell exhaustion and active cytotoxic T cell responses. Additionally, measure the levels of monocytes and macrophages within the tumor microenvironment. Finally, examine the most recent peer-reviewed studies to determine if these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"I have a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 9.0. Transcriptomic profiling of the tumor immune microenvironment was obtained from a bladder biopsy. Based on these data, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 9.0. Transcriptomic profiling of the tumor immune microenvironment was obtained from a bladder biopsy. Based on these data, what is the likelihood that the patient will respond to Atezolizumab therapy? Examine the tumor's gene expression profile to identify biomarkers that indicate both T cell exhaustion and active cytotoxic T cell responses. Additionally, quantify the presence of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed literature to assess whether these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"A Caucasian female patient with bladder urothelial carcinoma has a tumor mutational burden of 20.0, and we have the transcriptomic profile of her tumor's immune microenvironment from a bladder biopsy. Based on this molecular profile, what is the likelihood that she will respond favorably to Atezolizumab therapy?","A Caucasian female patient with bladder urothelial carcinoma has a tumor mutational burden of 20.0, and we have the transcriptomic profile of her tumor's immune microenvironment from a bladder biopsy. Based on this molecular profile, what is the likelihood that she will respond favorably to Atezolizumab therapy? Review the tumor's gene expression profile to detect biomarkers that reveal both T cell exhaustion and active cytotoxic responses. Also, measure the number of monocytes and macrophages present in the tumor microenvironment. Finally, consult recent peer-reviewed studies to determine if these biomarker patterns are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"In a white female patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy shows a tumor mutational burden of 10.0, what is the likelihood of a positive response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy shows a tumor mutational burden of 10.0, what is the likelihood of a positive response to Atezolizumab therapy? Examine the tumor’s gene expression profile to identify biomarkers that indicate both T cell exhaustion and active cytotoxic responses. Additionally, quantify the levels of monocytes and macrophages within the tumor microenvironment. Lastly, review recent peer-reviewed literature to assess whether these biomarker patterns are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutation burden (TMB) of 35, and transcriptomic profiling of his tumor immune microenvironment was obtained via bladder biopsy. Based on these findings, how likely is he to respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutation burden (TMB) of 35, and transcriptomic profiling of his tumor immune microenvironment was obtained via bladder biopsy. Based on these findings, how likely is he to respond to atezolizumab therapy? Review the tumor’s gene expression profile to identify biomarkers indicative of T cell exhaustion as well as those reflecting active cytotoxic responses. Additionally, determine the abundance of monocytes and macrophages within the tumor microenvironment. Finally, consult recent peer-reviewed studies to evaluate whether these biomarker patterns are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"In a white female patient with bladder urothelial carcinoma and a tumor mutation burden of 6.0, does the transcriptomic profile of the tumor immune microenvironment from her bladder biopsy suggest that she is likely to benefit from atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma and a tumor mutation burden of 6.0, does the transcriptomic profile of the tumor immune microenvironment from her bladder biopsy suggest that she is likely to benefit from atezolizumab therapy? Evaluate the tumor's gene expression data to identify biomarkers that indicate T cell exhaustion and, at the same time, detect markers of active cytotoxic activity. Also, quantify the levels of monocytes and macrophages in the tumor microenvironment. Lastly, review recent peer-reviewed studies to determine if these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 3.0 and a transcriptomic profile from her tumor immune microenvironment obtained via bladder biopsy, is it reasonable to expect a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 3.0 and a transcriptomic profile from her tumor immune microenvironment obtained via bladder biopsy, is it reasonable to expect a favorable response to Atezolizumab therapy? Assess the tumor’s gene expression profile by identifying biomarkers for T cell exhaustion alongside markers indicative of active cytotoxic activity. Quantify the presence of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed research to determine if these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"For a White male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0, and whose tumor immune microenvironment has been characterized through transcriptomic profiling of a bladder biopsy, would you expect a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0, and whose tumor immune microenvironment has been characterized through transcriptomic profiling of a bladder biopsy, would you expect a favorable response to Atezolizumab therapy? Evaluate the tumor's gene expression by identifying biomarkers associated with T cell exhaustion and markers indicative of active cytotoxic function. Additionally, quantify the levels of monocytes and macrophages in the tumor microenvironment. Finally, review recent peer-reviewed literature to assess whether these biomarker profiles are correlated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"Given a Caucasian male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been profiled via nano biopsy and shows a tumor mutational burden (TMB) of 5.0, is there evidence to suggest that Atezolizumab would be an effective therapy for him?","Given a Caucasian male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been profiled via nano biopsy and shows a tumor mutational burden (TMB) of 5.0, is there evidence to suggest that Atezolizumab would be an effective therapy for him? Assess the tumor’s gene expression by testing for biomarkers related to T cell exhaustion as well as those that signify active cytotoxic function. Also, determine the quantity of monocytes and macrophages present in the tumor microenvironment. Finally, consult recent peer-reviewed studies to evaluate whether these biomarker profiles are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"My white male patient has bladder urothelial carcinoma with a tumor mutational burden of 5.0. Based on the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, can we expect a favorable response to atezolizumab therapy?","My white male patient has bladder urothelial carcinoma with a tumor mutational burden of 5.0. Based on the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, can we expect a favorable response to atezolizumab therapy? Evaluate the tumor’s gene expression by measuring biomarkers that indicate T cell exhaustion and those that signal active cytotoxic function. Additionally, quantify the number of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed studies to determine if these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic immune profile from a kidney biopsy and a tumor mutational burden of 5.0. Based on these findings, what is the expected likelihood of a clinical response to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic immune profile from a kidney biopsy and a tumor mutational burden of 5.0. Based on these findings, what is the expected likelihood of a clinical response to atezolizumab therapy? Assess the tumor’s gene expression by quantifying biomarkers that reflect T cell exhaustion and markers of active cytotoxic function. Also, determine the number of monocytes and macrophages present in the tumor microenvironment. Lastly, evaluate recent peer-reviewed research to see if these biomarker profiles correlate with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"We have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via transcriptomic analysis from a bladder biopsy, but his tumor mutational burden (TMB) was not available. Based on these data, what is the likelihood that he will respond favorably to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via transcriptomic analysis from a bladder biopsy, but his tumor mutational burden (TMB) was not available. Based on these data, what is the likelihood that he will respond favorably to Atezolizumab therapy? Evaluate the tumor’s gene expression by quantifying biomarkers associated with T cell exhaustion and active cytotoxic function. Additionally, measure the density of monocytes and macrophages in the tumor microenvironment. Finally, review recent peer-reviewed studies to determine whether these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"One of my patients with bladder urothelial carcinoma (BLCA) recently underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment, and the results indicate a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","One of my patients with bladder urothelial carcinoma (BLCA) recently underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment, and the results indicate a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Assess the tumor's gene expression by quantifying biomarkers that indicate T cell exhaustion and active cytotoxic activity. Also, determine the concentration of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed studies to establish if these biomarker profiles are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has undergone a ureter biopsy with transcriptomic profiling of the tumor immune microenvironment and a tumor mutational burden (TMB) of 10, is there evidence to suggest that they would respond favorably to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has undergone a ureter biopsy with transcriptomic profiling of the tumor immune microenvironment and a tumor mutational burden (TMB) of 10, is there evidence to suggest that they would respond favorably to Atezolizumab therapy? Evaluate the tumor's gene expression by measuring biomarkers that reflect both T cell exhaustion and active cytotoxic function. Additionally, determine the levels of monocytes and macrophages within the tumor microenvironment. Finally, examine recent peer-reviewed studies to assess whether these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 3.0, how likely is it that he will respond to Atezolizumab therapy, considering the transcriptomic profile obtained from his lymph node biopsy?","For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 3.0, how likely is it that he will respond to Atezolizumab therapy, considering the transcriptomic profile obtained from his lymph node biopsy? Assess the tumor’s gene expression by quantifying biomarkers indicative of both T cell exhaustion and active cytotoxic activity. Also, measure the presence of monocytes and macrophages in the tumor microenvironment. Finally, review recent peer-reviewed literature to determine if these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"For a white male patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment (from a bladder biopsy) reveals a tumor mutation burden (TMB) of 3.0, is atezolizumab therapy expected to be effective?","For a white male patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment (from a bladder biopsy) reveals a tumor mutation burden (TMB) of 3.0, is atezolizumab therapy expected to be effective? Evaluate the tumor’s gene expression by quantifying biomarkers that signify T cell exhaustion and active cytotoxic function. Additionally, quantify the levels of monocytes and macrophages within the tumor microenvironment. Finally, consult recent peer-reviewed literature to assess whether these biomarker profiles correlate with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"Given a Black or African American female patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile from a lung biopsy and a tumor mutational burden (TMB) of 11.0, how likely is she to respond to Atezolizumab therapy?","Given a Black or African American female patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile from a lung biopsy and a tumor mutational burden (TMB) of 11.0, how likely is she to respond to Atezolizumab therapy? Assess the tumor's gene expression by measuring specific biomarkers that indicate T cell exhaustion as well as active cytotoxic function. Also, determine the densities of monocytes and macrophages in the tumor microenvironment. Finally, review the most recent peer-reviewed studies to evaluate if these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"My white male patient with bladder urothelial carcinoma underwent a lymph node biopsy, and we obtained a transcriptomic profile of the tumor immune microenvironment. However, his tumor mutational burden is reported as 'nan'. Based on these findings, can we predict whether he is likely to respond to atezolizumab therapy?","My white male patient with bladder urothelial carcinoma underwent a lymph node biopsy, and we obtained a transcriptomic profile of the tumor immune microenvironment. However, his tumor mutational burden is reported as 'nan'. Based on these findings, can we predict whether he is likely to respond to atezolizumab therapy? Evaluate the tumor’s gene expression by quantifying biomarkers that indicate both T cell exhaustion and active cytotoxic function. Additionally, measure the density of monocytes and macrophages present in the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, how should the transcriptomic profile of the tumor immune microenvironment from his liver biopsy inform our prediction of response to Atezolizumab therapy, given that his tumor mutational burden is indeterminate?","For a Caucasian male patient with bladder urothelial carcinoma, how should the transcriptomic profile of the tumor immune microenvironment from his liver biopsy inform our prediction of response to Atezolizumab therapy, given that his tumor mutational burden is indeterminate? Assess the tumor’s gene expression by quantifying biomarkers that reflect both T cell exhaustion and active cytotoxic function. At the same time, determine the density of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to evaluate whether these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"In a white female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 26.0, what is the likelihood that she will respond favorably to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 26.0, what is the likelihood that she will respond favorably to atezolizumab therapy? Evaluate the tumor’s gene expression profile by quantitatively measuring biomarkers that indicate T cell exhaustion as well as those reflective of active cytotoxic function. Simultaneously, determine the density of monocytes and macrophages present within the tumor microenvironment. Finally, review current peer-reviewed studies to assess whether these biomarker profiles are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"Given a white male patient with bladder urothelial carcinoma (BLCA), who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden (TMB) of 14.0, what is the likelihood of a positive response to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma (BLCA), who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden (TMB) of 14.0, what is the likelihood of a positive response to Atezolizumab therapy? Assess the tumor’s gene expression by quantitatively measuring biomarkers that signal T cell exhaustion and those associated with active cytotoxic function. At the same time, measure the density of monocytes and macrophages within the tumor microenvironment. Lastly, review recent peer-reviewed research to determine if these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment obtained from a lung biopsy, and the tumor mutational burden (TMB) is reported as “nan.” Based on this information, is it reasonable to expect that he will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment obtained from a lung biopsy, and the tumor mutational burden (TMB) is reported as “nan.” Based on this information, is it reasonable to expect that he will respond to atezolizumab therapy? Quantitatively evaluate the tumor’s gene expression by measuring biomarkers that reflect both T cell exhaustion and active cytotoxic function. Simultaneously, determine the density of monocytes and macrophages in the tumor microenvironment. Finally, consult recent peer-reviewed studies to assess whether these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"For a white female patient diagnosed with bladder urothelial carcinoma, with a tumor immune microenvironment transcriptomic profile obtained from a ureter biopsy and a tumor mutational burden of 4.0, what is the anticipated response to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, with a tumor immune microenvironment transcriptomic profile obtained from a ureter biopsy and a tumor mutational burden of 4.0, what is the anticipated response to atezolizumab therapy? Assess the tumor’s gene expression quantitatively by measuring biomarkers that indicate both T cell exhaustion and active cytotoxic function. Additionally, determine the density of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed research to evaluate whether these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 3.0 mutations/Mb. Based on these findings, what is the anticipated response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 3.0 mutations/Mb. Based on these findings, what is the anticipated response to Atezolizumab therapy? Perform a quantitative evaluation of the tumor’s gene expression by measuring biomarkers specific to T cell exhaustion as well as active cytotoxic function. Additionally, assess the density of monocytes and macrophages in the tumor microenvironment. Finally, review the most recent peer-reviewed studies to determine if these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"I have a white male patient with a confirmed diagnosis of bladder urothelial carcinoma. The tumor biopsy transcriptomic profile of the immune microenvironment is available, and the tumor mutational burden (TMB) is 22.0 mutations/Mb. Based on these findings, what is the likelihood that the patient will have a favorable response to Atezolizumab therapy?","I have a white male patient with a confirmed diagnosis of bladder urothelial carcinoma. The tumor biopsy transcriptomic profile of the immune microenvironment is available, and the tumor mutational burden (TMB) is 22.0 mutations/Mb. Based on these findings, what is the likelihood that the patient will have a favorable response to Atezolizumab therapy? Evaluate the tumor’s gene expression by quantitatively measuring biomarkers associated with T cell exhaustion and active cytotoxic function. Also, determine the density of monocytes and macrophages in the tumor microenvironment. Finally, review current, peer-reviewed research to assess whether these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor's immune microenvironment from a bladder biopsy; however, his tumor mutation burden (TMB) is not available. Based on this information, can we reasonably predict his response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor's immune microenvironment from a bladder biopsy; however, his tumor mutation burden (TMB) is not available. Based on this information, can we reasonably predict his response to Atezolizumab therapy? Quantitatively assess the tumor's gene expression by measuring biomarkers indicative of T cell exhaustion and active cytotoxic activity. Also, quantify the population of monocytes and macrophages within the tumor microenvironment. Lastly, consult current, peer-reviewed literature to determine if these biomarker profiles are associated with enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, a tumor mutation burden of 3.0, and a lymph node biopsy transcriptomic profile of the tumor immune microenvironment, what is her likelihood of responding to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, a tumor mutation burden of 3.0, and a lymph node biopsy transcriptomic profile of the tumor immune microenvironment, what is her likelihood of responding to atezolizumab therapy? Please perform a quantitative analysis of the tumor's gene expression by measuring biomarkers that indicate both T cell exhaustion and active cytotoxic responses. Additionally, count the monocyte and macrophage populations within the tumor microenvironment. Finally, review the current peer-reviewed literature to determine if these specific biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"For a white male patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 62.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 62.0, what is the likelihood of a favorable response to atezolizumab therapy? Conduct a quantitative gene expression analysis of the tumor by measuring biomarkers associated with T cell exhaustion and cytotoxic activity. Additionally, determine the counts of monocytes and macrophages within the tumor microenvironment. Lastly, review the latest peer-reviewed studies to assess whether these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"My patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 14.0, and we have transcriptomic profiling data of the tumor immune microenvironment from a previous biopsy. Based on these findings, do you anticipate a favorable response to Atezolizumab therapy?","My patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 14.0, and we have transcriptomic profiling data of the tumor immune microenvironment from a previous biopsy. Based on these findings, do you anticipate a favorable response to Atezolizumab therapy? Perform a quantitative gene expression analysis on the tumor tissue by evaluating biomarkers indicative of T cell exhaustion and cytotoxic activity. In addition, quantify the presence of monocytes and macrophages within the tumor microenvironment. Finally, consult the latest peer-reviewed literature to determine whether these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"Our patient, a white male with bladder urothelial carcinoma, has a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 7.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","Our patient, a white male with bladder urothelial carcinoma, has a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 7.0. Based on these findings, how likely is he to respond to atezolizumab therapy? Conduct a quantitative gene expression analysis on the tumor tissue to assess biomarkers associated with T cell exhaustion and cytotoxic function. Also, quantify the levels of monocytes and macrophages present in the tumor microenvironment. Finally, review the latest peer-reviewed studies to determine if these biomarker profiles are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"In a patient with bladder urothelial carcinoma who has a tumor mutation burden of 15.0 and a transcriptomic profile of the tumor's immune microenvironment obtained from a bladder biopsy, is Atezolizumab likely to be effective as a therapeutic option?","In a patient with bladder urothelial carcinoma who has a tumor mutation burden of 15.0 and a transcriptomic profile of the tumor's immune microenvironment obtained from a bladder biopsy, is Atezolizumab likely to be effective as a therapeutic option? Please perform a quantitative analysis of gene expression on the tumor tissue to evaluate biomarkers associated with T cell exhaustion and cytotoxic function. Additionally, measure the levels of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed literature to assess whether these biomarker profiles are linked to improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, would you expect a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, would you expect a favorable response to atezolizumab therapy? Please conduct a quantitative gene expression analysis on the tumor tissue, focusing on biomarkers that indicate T cell exhaustion and cytotoxic activity. In addition, assess the levels of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed literature to determine if these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden data is not available, how should we interpret the potential response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden data is not available, how should we interpret the potential response to Atezolizumab therapy? Please perform a quantitative gene expression analysis on tumor tissue to assess biomarkers for T cell exhaustion and cytotoxic activity. Additionally, measure the abundance of monocytes and macrophages in the tumor microenvironment. Finally, review recent peer-reviewed studies to evaluate whether these biomarker profiles are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"I am managing a white female patient with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of her tumor immune microenvironment from a ureteral biopsy. Given that her tumor mutational burden (TMB) is unavailable (NaN), could you provide insights on the likelihood of a positive response to atezolizumab therapy based on these findings?","I am managing a white female patient with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of her tumor immune microenvironment from a ureteral biopsy. Given that her tumor mutational burden (TMB) is unavailable (NaN), could you provide insights on the likelihood of a positive response to atezolizumab therapy based on these findings? Conduct a quantitative gene expression analysis on the tumor tissue to evaluate biomarkers indicative of T cell exhaustion and cytotoxic activity. In addition, quantify the presence of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine whether these specific biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"Given a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 24.0 and available transcriptomic data from a bladder biopsy of the tumor immune microenvironment, is there evidence to suggest that this patient would respond favorably to atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 24.0 and available transcriptomic data from a bladder biopsy of the tumor immune microenvironment, is there evidence to suggest that this patient would respond favorably to atezolizumab therapy? Please perform a quantitative gene expression analysis on the tumor specimen to assess markers associated with T cell exhaustion and cytotoxic activity. Additionally, measure the abundance of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to determine whether these biomarker profiles are linked to better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden (TMB) is not available. Based on these data, is he likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden (TMB) is not available. Based on these data, is he likely to respond to atezolizumab therapy? Please conduct a quantitative analysis of gene expression on the tumor sample to evaluate markers indicative of T cell exhaustion and cytotoxic function. In addition, quantify the levels of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed research to determine whether these biomarker profiles correlate with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy and a tumor mutational burden (TMB) of 8.0. Given these findings, is he likely to respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy and a tumor mutational burden (TMB) of 8.0. Given these findings, is he likely to respond to Atezolizumab therapy? Please perform a quantitative gene expression analysis on the tumor sample, specifically assessing markers of T cell exhaustion and cytotoxic function. Additionally, quantify the monocyte and macrophage populations within the tumor microenvironment. Finally, review recent peer-reviewed literature to evaluate whether the profiles of these biomarkers are associated with better treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"We have a white male patient with bladder urothelial carcinoma (BLCA) who presents a tumor mutation burden (TMB) of 4.0. Given the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma (BLCA) who presents a tumor mutation burden (TMB) of 4.0. Given the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy? Please conduct a quantitative gene expression analysis on the tumor sample, focusing on markers that indicate T cell exhaustion and cytotoxic activity. Additionally, quantify the monocyte and macrophage populations present in the tumor microenvironment. Finally, review current peer-reviewed research to determine if these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"Our Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, along with a tumor mutational burden (TMB) of 14.0. Based on these results, what is the likelihood that the patient will respond to Atezolizumab therapy?","Our Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, along with a tumor mutational burden (TMB) of 14.0. Based on these results, what is the likelihood that the patient will respond to Atezolizumab therapy? Please perform a quantitative gene expression analysis of the tumor sample, emphasizing markers that signal T cell exhaustion and cytotoxic activity. In addition, quantify the monocyte and macrophage populations within the tumor microenvironment. Finally, assess current peer-reviewed research to determine whether these biomarker profiles are linked to enhanced treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 5.0, how does the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy inform the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 5.0, how does the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy inform the likelihood of a positive response to Atezolizumab therapy? Please conduct a quantitative gene expression analysis on the tumor sample, focusing on markers that indicate T cell exhaustion and cytotoxic activity. Additionally, measure the populations of monocytes and macrophages within the tumor microenvironment. Finally, review the current peer-reviewed literature to evaluate whether these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a TMB of 10.0 and transcriptomic data from a bladder biopsy focusing on the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a TMB of 10.0 and transcriptomic data from a bladder biopsy focusing on the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy? Please perform a quantitative assessment of gene expression on the tumor sample, specifically targeting markers indicative of T cell exhaustion and cytotoxic activity. Additionally, quantify the populations of monocytes and macrophages present within the tumor microenvironment. Finally, review the current peer-reviewed literature to determine if these biomarker profiles are associated with improved treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Given that the tumor mutation burden (TMB) is not available (nan), can we expect that the patient will respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Given that the tumor mutation burden (TMB) is not available (nan), can we expect that the patient will respond to Atezolizumab therapy? Evaluate the tumor sample by quantitatively measuring gene expression, particularly focusing on markers related to T cell exhaustion and cytotoxic function. In addition, determine the numbers of monocytes and macrophages within the tumor microenvironment. Finally, examine recent peer-reviewed articles to assess whether these biomarker profiles are linked to better patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"I have a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled transcriptomically from a lymph node biopsy, and the reported tumor mutational burden is 'nan.' Based on these findings, is there evidence to support the likelihood of a favorable response to Atezolizumab therapy?","I have a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled transcriptomically from a lymph node biopsy, and the reported tumor mutational burden is 'nan.' Based on these findings, is there evidence to support the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor specimen by quantitatively assessing gene expression, with a specific focus on markers indicative of T cell exhaustion and cytotoxic activity. Additionally, quantify the number of monocytes and macrophages present within the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarker profiles correlate with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"Given a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 19.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 19.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Analyze the tumor sample by quantitatively measuring gene expression, focusing specifically on markers of T cell exhaustion as well as indicators of cytotoxic function. Additionally, count the monocytes and macrophages within the tumor microenvironment. Finally, review up-to-date peer-reviewed studies to determine if these biomarker profiles are associated with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"For a patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a ureteral biopsy and a tumor mutational burden of 5.0, would Atezolizumab therapy be expected to be effective?","For a patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a ureteral biopsy and a tumor mutational burden of 5.0, would Atezolizumab therapy be expected to be effective? Please perform a quantitative gene expression analysis of the tumor sample, concentrating on markers indicative of T cell exhaustion and cytotoxic function. In addition, enumerate the monocytes and macrophages present in the tumor microenvironment. Lastly, review the latest peer-reviewed literature to determine whether these biomarker profiles are linked to enhanced patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 2.0. Additionally, we have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. Based on these findings, could you advise on the likelihood of her responding to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 2.0. Additionally, we have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. Based on these findings, could you advise on the likelihood of her responding to Atezolizumab therapy? Perform a quantitative gene expression analysis of the tumor sample, focusing on markers of T cell exhaustion and cytotoxic function. Additionally, quantify the monocytes and macrophages present in the tumor microenvironment. Finally, review the most recent peer-reviewed studies to assess whether these biomarker profiles correlate with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"A Caucasian male with bladder urothelial carcinoma has a tumor mutational burden of 14.0 and transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. Based on this data, how likely is he to benefit from atezolizumab therapy?","A Caucasian male with bladder urothelial carcinoma has a tumor mutational burden of 14.0 and transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy. Based on this data, how likely is he to benefit from atezolizumab therapy? Please conduct a quantitative analysis of gene expression on the tumor sample, specifically assessing markers of T cell exhaustion and cytotoxic function. Additionally, quantify the number of monocytes and macrophages in the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine if these biomarker profiles are associated with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"We have a white female patient diagnosed with bladder urothelial carcinoma. A nanobiopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden is 17.0. Based on this information, what is the likelihood that she will benefit from Atezolizumab therapy?","We have a white female patient diagnosed with bladder urothelial carcinoma. A nanobiopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden is 17.0. Based on this information, what is the likelihood that she will benefit from Atezolizumab therapy? Please perform a quantitative gene expression analysis on the tumor sample, focusing on markers that indicate T cell exhaustion and cytotoxic function. Also, determine the counts of monocytes and macrophages within the tumor microenvironment. Additionally, review current peer-reviewed literature to evaluate whether these biomarker profiles are linked to improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"I am managing a white male patient with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. With the tumor mutational burden (TMB) not available, can we determine whether he is likely to respond to Atezolizumab therapy?","I am managing a white male patient with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. With the tumor mutational burden (TMB) not available, can we determine whether he is likely to respond to Atezolizumab therapy? Please conduct a quantitative gene expression assessment of the tumor sample, with a particular focus on markers indicative of T cell exhaustion and cytotoxic function. In addition, quantify the number of monocytes and macrophages present within the tumor microenvironment. Finally, review the latest peer-reviewed literature to determine whether these biomarker profiles are associated with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"For my white male patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 6.0, should we expect a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 6.0, should we expect a favorable response to Atezolizumab therapy? Please perform a quantitative analysis of gene expression in the tumor sample, specifically targeting markers for T cell exhaustion and cytotoxic function. Additionally, determine the counts of monocytes and macrophages present in the tumor microenvironment. Finally, review recent peer-reviewed publications to assess whether these biomarker profiles are linked to better patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"For a White female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 9.0, would you expect a favorable response to Atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 9.0, would you expect a favorable response to Atezolizumab therapy? Please quantitatively evaluate gene expression in the tumor specimen, focusing on markers of T cell exhaustion and cytotoxic activity. Additionally, quantify the number of monocytes and macrophages in the tumor microenvironment. Finally, review recent peer-reviewed literature to determine if these biomarker profiles are associated with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"For a white female patient with bladder urothelial carcinoma, given that we have transcriptomic data from a kidney biopsy of her tumor immune microenvironment and her tumor mutation burden is 5.0, is she likely to respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, given that we have transcriptomic data from a kidney biopsy of her tumor immune microenvironment and her tumor mutation burden is 5.0, is she likely to respond to Atezolizumab therapy? Perform a quantitative analysis of gene expression in the tumor sample, with specific attention to markers indicative of T cell exhaustion and cytotoxic function. In addition, please determine the counts of monocytes and macrophages present in the tumor microenvironment. Finally, review the latest peer-reviewed studies to ascertain whether these biomarker profiles correlate with better patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor's immune microenvironment from a liver biopsy and a tumor mutational burden of 5.0. Based on these findings, is he likely to respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor's immune microenvironment from a liver biopsy and a tumor mutational burden of 5.0. Based on these findings, is he likely to respond to atezolizumab therapy? Please conduct a quantitative assessment of gene expression in the tumor sample, focusing specifically on markers associated with T cell exhaustion and cytotoxic function. Additionally, quantify the number of monocytes and macrophages in the tumor microenvironment. Finally, review current peer-reviewed literature to evaluate whether these biomarker profiles are associated with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile available from a bladder biopsy, detailing his tumor immune microenvironment. However, his tumor mutational burden (TMB) is listed as ""nan."" Based on this data, what is the likelihood that the patient will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile available from a bladder biopsy, detailing his tumor immune microenvironment. However, his tumor mutational burden (TMB) is listed as ""nan."" Based on this data, what is the likelihood that the patient will respond to atezolizumab therapy? Please quantitatively assess gene expression in the tumor sample, concentrating on markers linked to T cell exhaustion and cytotoxic activity. Also, determine the counts of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed research to determine if these biomarker patterns correlate with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy and who has an unavailable tumor mutational burden, can we predict a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy and who has an unavailable tumor mutational burden, can we predict a positive response to atezolizumab therapy? Quantify gene expression in the tumor specimen, focusing on markers indicative of T cell exhaustion and cytotoxic activity. Additionally, enumerate monocytes and macrophages in the tumor microenvironment. Then, review recent peer-reviewed studies to determine whether these biomarker profiles are associated with better patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 7.0, based on transcriptomic profiling of his tumor immune microenvironment from a kidney biopsy, is there evidence to suggest he may respond favorably to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 7.0, based on transcriptomic profiling of his tumor immune microenvironment from a kidney biopsy, is there evidence to suggest he may respond favorably to Atezolizumab therapy? Measure the expression levels of genes associated with T cell exhaustion and cytotoxic activity in the tumor sample. Additionally, count the numbers of monocytes and macrophages present within the tumor microenvironment. Following this, review current peer-reviewed literature to assess whether these biomarker profiles correlate with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma presenting with a tumor mutation burden of 1.0, and given the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma presenting with a tumor mutation burden of 1.0, and given the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please determine the expression levels of genes involved in T cell exhaustion and cytotoxic activity in the tumor sample. Also, quantify the numbers of monocytes and macrophages within the tumor microenvironment. Afterward, review recent peer-reviewed studies to evaluate if these biomarker profiles are associated with better patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, but the tumor mutational burden value is not available. Based on these findings, what is the likelihood that the patient would respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, but the tumor mutational burden value is not available. Based on these findings, what is the likelihood that the patient would respond to Atezolizumab therapy? Assess the expression levels of genes associated with T cell exhaustion and cytotoxic function in the tumor sample. Additionally, quantify monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to determine if these biomarker profiles are linked to improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been characterized using transcriptomic profiling from a bladder biopsy and who has a TMB of 6.0, is Atezolizumab likely to be an effective treatment option?","In a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been characterized using transcriptomic profiling from a bladder biopsy and who has a TMB of 6.0, is Atezolizumab likely to be an effective treatment option? Evaluate the gene expression of markers associated with T cell exhaustion and cytotoxic activity in the tumor tissue. In parallel, determine the abundance of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed studies to assess whether these biomarker profiles correlate with improved patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of her tumor immune microenvironment from a bladder biopsy is available, and her tumor mutational burden is 3.0. Based on these findings, how likely is she to respond to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of her tumor immune microenvironment from a bladder biopsy is available, and her tumor mutational burden is 3.0. Based on these findings, how likely is she to respond to atezolizumab therapy? Assess the expression levels of genes associated with T cell exhaustion and cytotoxic activity in tumor tissue samples. Concurrently, quantify the abundance of monocytes and macrophages in the tumor microenvironment. Finally, review recent peer-reviewed studies to determine if these biomarker profiles are linked to improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"Given a white male patient with bladder urothelial carcinoma (BLCA), a TMB of 7.0, and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest he would respond favorably to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma (BLCA), a TMB of 7.0, and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest he would respond favorably to Atezolizumab therapy? Evaluate the gene expression levels of markers for T cell exhaustion and cytotoxic activity in tumor tissue samples. Simultaneously, measure the populations of monocytes and macrophages present in the tumor microenvironment. Finally, review recent peer-reviewed literature to establish whether these biomarker profiles correlate with better clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"We have a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy provided transcriptomic profiling of the tumor immune microenvironment, and his tumor mutational burden is 14.0. Given these findings, what is his likelihood of responding to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy provided transcriptomic profiling of the tumor immune microenvironment, and his tumor mutational burden is 14.0. Given these findings, what is his likelihood of responding to Atezolizumab therapy? Assess the expression of gene markers linked to T cell exhaustion and cytotoxic function in tumor samples. Concurrently, quantify the infiltration of monocytes and macrophages within the tumor microenvironment. Then, review current peer-reviewed studies to ascertain whether these biomarker profiles are associated with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutation burden of 2.0 and whose tumor immune microenvironment was profiled via kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutation burden of 2.0 and whose tumor immune microenvironment was profiled via kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Evaluate the levels of gene expression related to T cell exhaustion and cytotoxic functions in tumor samples. At the same time, quantify the presence of monocytes and macrophages within the tumor microenvironment. Finally, review the latest peer-reviewed studies to determine if these biomarker profiles are linked to improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy for transcriptomic profiling of the tumor immune microenvironment. Considering that the tumor mutational burden is not available, what is the likelihood that this patient will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy for transcriptomic profiling of the tumor immune microenvironment. Considering that the tumor mutational burden is not available, what is the likelihood that this patient will respond to atezolizumab therapy? Assess gene expression levels associated with T cell exhaustion and cytotoxic activity in tumor specimens. Concurrently, measure the abundance of monocytes and macrophages within the tumor microenvironment. Additionally, review current peer-reviewed research to determine whether these biomarker patterns correlate with better clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), and we obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy. Considering that the tumor mutational burden data are unavailable (TMB: nan), can we predict his likelihood of responding to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), and we obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy. Considering that the tumor mutational burden data are unavailable (TMB: nan), can we predict his likelihood of responding to Atezolizumab therapy? Evaluate the expression levels of genes related to T cell exhaustion and cytotoxic function in tumor tissue samples. At the same time, quantify the number of monocytes and macrophages present in the tumor microenvironment. Finally, review recent peer-reviewed studies to determine if these biomarker profiles are associated with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled via transcriptomics from a lung biopsy and who has a TMB of 1.0, is Atezolizumab therapy likely to be effective?","In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled via transcriptomics from a lung biopsy and who has a TMB of 1.0, is Atezolizumab therapy likely to be effective? Assess the levels of gene expression associated with T cell exhaustion and cytotoxic activity in tumor tissue samples. Concurrently, count the monocytes and macrophages within the tumor microenvironment. Finally, critically review recent peer-reviewed literature to determine whether these biomarker profiles correlate with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, how likely is it that he would respond favorably to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, how likely is it that he would respond favorably to atezolizumab therapy? Evaluate the expression of genes linked to T cell exhaustion and cytotoxic activity in tumor tissue samples. Simultaneously, quantify the numbers of monocytes and macrophages present within the tumor microenvironment. Additionally, review recent peer-reviewed studies to determine if these biomarker profiles are associated with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using transcriptomic analysis from a kidney biopsy. With a tumor mutational burden (TMB) of 14.0, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using transcriptomic analysis from a kidney biopsy. With a tumor mutational burden (TMB) of 14.0, what is the likelihood that he will respond to Atezolizumab therapy? Assess gene expression of markers associated with T cell exhaustion and cytotoxic function in tumor tissue samples. At the same time, quantify the monocyte and macrophage populations within the tumor microenvironment. Finally, review recent peer-reviewed studies to determine if these biomarker profiles correlate with better clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"In a Black or African American patient with bladder urothelial carcinoma (BLCA) who has a tumor transcriptomic profile of the immune microenvironment and a tumor mutational burden of 9.0, what is the likelihood of response to Atezolizumab therapy?","In a Black or African American patient with bladder urothelial carcinoma (BLCA) who has a tumor transcriptomic profile of the immune microenvironment and a tumor mutational burden of 9.0, what is the likelihood of response to Atezolizumab therapy? Please evaluate tumor tissue samples by measuring the gene expression of markers linked to T cell exhaustion and cytotoxic activity. Concurrently, quantify the populations of monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to determine whether these biomarker profiles are associated with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA), based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 8.0, what is the likelihood of a favorable response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA), based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 8.0, what is the likelihood of a favorable response to atezolizumab therapy? Evaluate the tumor tissue samples by quantifying gene expression levels of markers associated with T cell exhaustion and cytotoxic function. In parallel, determine the number of monocytes and macrophages present in the tumor microenvironment. Then, consult recent peer-reviewed studies to assess whether these biomarker profiles correlate with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile characterizes the tumor immune microenvironment and who has a tumor mutation burden of 7.0, what is the likelihood that she will respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile characterizes the tumor immune microenvironment and who has a tumor mutation burden of 7.0, what is the likelihood that she will respond to Atezolizumab therapy? Review the tumor tissue samples to measure the gene expression of markers for T cell exhaustion and cytotoxic function. At the same time, count the monocytes and macrophages within the tumor microenvironment. Finally, consult the latest peer-reviewed literature to determine if these biomarker profiles are associated with better clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"In an Asian female patient with bladder urothelial carcinoma, where a kidney biopsy revealed the transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 4.0, is atezolizumab therapy likely to be effective?","In an Asian female patient with bladder urothelial carcinoma, where a kidney biopsy revealed the transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 4.0, is atezolizumab therapy likely to be effective? Please examine the tumor tissue samples and quantify the gene expression of markers related to T cell exhaustion and cytotoxic function. Additionally, count the monocytes and macrophages within the tumor microenvironment. Finally, review current peer-reviewed literature to assess whether these biomarker profiles correlate with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 7 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the anticipated response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 7 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the anticipated response to Atezolizumab therapy? Review tumor tissue samples to quantify the gene expression of markers associated with T cell exhaustion and cytotoxic activity. Additionally, count the monocytes and macrophages present in the tumor microenvironment. Finally, examine recent peer-reviewed studies to determine if these biomarker profiles are linked to better clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden is reported as unavailable (NaN). Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden is reported as unavailable (NaN). Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Evaluate tumor tissue samples by quantifying gene expression levels for markers that indicate T cell exhaustion and cytotoxic function. Additionally, assess the number of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed literature to determine whether these biomarker profiles are associated with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and available transcriptomic data on the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and available transcriptomic data on the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please analyze tumor tissue samples by measuring gene expression levels for markers that indicate T cell exhaustion as well as cytotoxic activity. Also, determine the numbers of monocytes and macrophages present in the tumor microenvironment. Finally, review the latest peer-reviewed literature to assess whether these biomarker profiles correlate with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"For a white female patient with bladder urothelial carcinoma, given a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 7.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, given a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 7.0, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate tumor tissue samples by quantifying gene expression for markers indicative of T cell exhaustion and cytotoxic function. Additionally, determine the number of monocytes and macrophages within the tumor microenvironment. Finally, review recent peer-reviewed literature to assess if these biomarker profiles are associated with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 10.0 and available transcriptomic data of the tumor immune microenvironment from a previous biopsy. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 10.0 and available transcriptomic data of the tumor immune microenvironment from a previous biopsy. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Please assess tumor tissue specimens by measuring gene expression for markers associated with T cell exhaustion and cytotoxic activity. In addition, quantify the populations of monocytes and macrophages present in the tumor microenvironment. Lastly, review the latest peer-reviewed studies to determine if these biomarker profiles correlate with improved clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
